

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/62, C07K 19/00, 14/505, C12N 15/85, 5/10, A61K 38/18		A1	(11) International Publication Number: WO 99/02710 (43) International Publication Date: 21 January 1999 (21.01.99)
(21) International Application Number: PCT/US98/13944 (22) International Filing Date: 9 July 1998 (09.07.98)		(74) Agents: HOGLE, Doreen, M. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02421 (US).	
(30) Priority Data: 08/890,929 10 July 1997 (10.07.97) US 09/018,138 3 February 1998 (03.02.98) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIGO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 08/890,929 (CIP) Filed on 10 July 1997 (10.07.97) US 09/018,138 (CIP) Filed on 3 February 1998 (03.02.98)		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (<i>for all designated States except US</i>): BETH ISRAEL DEACONESS MEDICAL CENTER [US/US]; 330 Brookline Avenue, Boston, MA 02215 (US). (72) Inventor; and (75) Inventor/Applicant (<i>for US only</i>): SYTKOWSKI, Arthur, J. [US/US]; 203 Park Avenue, Arlington, MA 02174 (US).			
(54) Title: PRODUCTION AND USE OF RECOMBINANT PROTEIN MULTIMERS WITH ALTERED BIOLOGICAL ACTIVITY			
(57) Abstract			
<p>The invention relates to recombinant fusion proteins, either with or without peptide linkers, with or without variations in noncoding regions of the protein. The fusion proteins have altered structural and functional properties and biological activity. The fusion proteins can be used, for example, as <i>in vivo</i> therapeutics.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Montenegro	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

-1-

PRODUCTION AND USE OF RECOMBINANT PROTEIN MULTIMERS
WITH ALTERED BIOLOGICAL ACTIVITY

RELATED APPLICATIONS

This application is a continuation-in-part application
5 of U.S. Serial No. 09/018,138, filed February 3, 1998,
which is a continuation-in-part application of U.S. Serial
No. 08/890,929, filed July 10, 1997, the teachings of which
are incorporated herein by reference, in their entirety.

GOVERNMENT SUPPORT

10 This invention was made, in whole or in part, with
Government support under Contract No. N00014-90-J-1847
awarded by the U.S. Navy. The Government has certain
rights in the invention.

BACKGROUND OF THE INVENTION

15 A problem encountered in the practice of medicine when
using proteins as injectable pharmaceuticals is the
frequency at which those injections must be made in order
to maintain a therapeutic level of the protein in the
circulation. For example, erythropoietin has a relatively
20 short plasma half-life (Spivak, J.L., and Hogans, B.B.,
Blood, 73:90, 1989; McMahon, F.G., et al., *Blood*, 76:1718,
1990). Therefore, therapeutic plasma levels are rapidly

-2-

decreased, and repeated intravenous administrations must be made. An alternative route of administration is subcutaneous injection. This route offers slower absorption from the site of administration, thus causing a 5 sustained release effect. However, significantly lower plasma levels are achieved and, thus, a similar frequency of injection, as is required with intravenous administration, must be used to produce a comparable therapeutic effect.

10 Modification of naturally occurring proteins which have therapeutic value is often attempted in an effort to increase the protein's biological activity. Several methods have been employed to increase the biological activity of therapeutic proteins. These methods often 15 focus on increasing the size of the therapeutic agents. For example, the size of a protein can be increased through chemical conjugation with a reagent such as polyethylene glycol (PEG) (Knusli, C., et al., *Brit. J. Haematol.* 82:654-663, 1992). This procedure, also known as 20 "PEGylation", has been reported with several protein agents, first as a means to reduce antigenicity, but also as a way to increase biological activity.

Another method of increasing a protein's size is through chemical cross-linking with another protein. For 25 example, to increase the antigenicity of a protein, chemical cross-linking agents are used to conjugate the immunogenic protein to a carrier molecule such as immunoglobulin or serum albumin.

-3-

However, the conjugation of chemical compounds or inert molecules to a protein often results in a significant decrease of the overall biological activity, and of selected biological activity of the protein. (Knusli, C., 5 et al., *Brit. J. Haematol.*, 82:654-663, 1992). These conjugations must be designed such that the resulting modified protein remains therapeutically efficacious and retains the desired biological properties of the unmodified, wild type (i.e., naturally-occurring) protein 10 (Satake, R., et al., *Biochem. Biophys. Acta*. 1038:125-129, 1990). Thus, it would be advantageous to be able to modify therapeutically active proteins to increase their biological activity which would result in less frequent injections or smaller doses of protein.

15 SUMMARY OF THE INVENTION

The present invention relates to modified proteins or polypeptides with increased biological activity, and methods of producing and using these modified proteins and polypeptides.

20 Increased biological activity results from the production of fusion proteins that result in protein multimers, e.g., dimers and trimers. Protein multimers are produced by expressing tandemly linked nucleic acids encoding the proteins of the present invention, or 25 biologically active fragments, analogs, variants, mutants or derivatives of the proteins. The nucleic acids that encode the proteins are fused, as described herein. The

-4-

proteins of the present invention can be fused directly to another protein, or can be fused via a linker, e.g., a peptide linker. The tandemly fused nucleic acid sequence is then inserted into an expression vector and introduced into 5 a competent cell, either prokaryotic or eukaryotic, resulting in the production of a fusion protein multimer with increased biological activity.

Increased biological activity is defined herein as a prolonged plasma half-life (that is, a longer circulating 10 half-life relative to the naturally occurring protein), or higher potency (i.e., requiring a smaller quantity relative to the naturally occurring protein to achieve a specified level of biological activity). Biological activity is also defined herein as greater affinity for receptors on target 15 cells, or increased cell signaling (i.e., increased protein tyrosine kinase activity, induction of receptor clustering or aggregation, reduced receptor mediated endocytosis, reduced susceptibility to degradation such as proteolysis), or increased stability or half-life of the fusion protein 20 during protein synthesis or the transcript encoding the fusion protein described herein. Increased biological activity can also encompass a combination of the above-described activities, for example, a modified protein with higher potency that also exhibits a prolonged circulating 25 half-life. Because the proteins of the present invention have increased biological activity, the frequency with which they must be administered is reduced, or the amount administered to achieve an effective dose is reduced.

-5-

Additional advantages can also result from the modifications described herein. For example, new unpredictable activities can result, such as increased affinity for receptors or binding ligands, which can result 5 in increased stimulation of signal generated by such binding. A reduced quantity of modified protein would then be necessary over the course of treatment as compared to the quantity necessary if unmodified protein were used.

Alternatively, or additionally, advantages can be 10 augmented secretion rates and increased stability of the fusion protein during protein synthesis from host cells thereby increasing the overall yield of the fusion protein produced by, for example, *in vitro* methods or when introduced into a host cell for *in vivo* therapeutic 15 purposes.

Proteins encompassed by the present invention include any protein with therapeutic activity. Specifically encompassed by the present invention are cytokines, growth factors, and hormones which include, for example, the 20 following: Interferon- α , Interferon- β , Interferon- γ , Interleukin-1, Interleukin-2, Interleukin-3, Interleukin-4, Interleukin-5, Interleukin-6, Interleukin-7, Interleukin-8, Interleukin-9, Interleukin-10, Interleukin-11, Interleukin-12, Interleukin-13, Interleukin-14, Interleukin-15, 25 Interleukin-16, Erythropoietin, Colony-Stimulating Factor-1, Granulocyte Colony-Stimulating Factor, Granulocyte-Macrophage Colony-Stimulating Factor, Leukemia Inhibitory Factor, Tumor Necrosis Factor, Lymphotoxin, Platelet-

-6-

- Derived Growth Factor, Fibroblast Growth Factors, Vascular Endothelial Cell Growth Factor, Epidermal Growth Factor, Transforming Growth Factor- β , Transforming Growth Factor- α , Thrombopoietin, Stem Cell Factor, Oncostatin M,
- 5 Amphiregulin, Mullerian-Inhibiting Substance, B-Cell Growth Factor, Macrophage Migration Inhibiting Factor, Endostatin, and Angiostatin. Exemplary descriptions and discussions of many of these proteins, including additional references for the manufacturing of proteins by recombinant
- 10 technologies, protein purification schemes, and assessment of biological activity, can be found in "*Human Cytokines: Handbook for Basic and Clinical Research*", Aggarwal, B.B., and Guterman, J.U., Eds., Blackwell Scientific Publications, Boston, MA, (1992), which is herein
- 15 incorporated by reference in its entirety.

More specifically, the present invention relates to modified erythropoietin with increased biological activity, as defined herein. The modified erythropoietin with increased biological activity of the present invention is a

20 fusion protein comprising two or more erythropoietin molecules covalently fused, resulting in an erythropoietin multimer.

Also encompassed by the present invention are methods of making and using the fusion protein multimers described

25 herein and methods of using them.

The present invention provides fusion proteins with increased biological activity. As a result of the present

-7-

invention, the fusion proteins described herein provide proteins with improved therapeutic value.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a diagram showing an EPO-EPO dimer DNA construct comprising an EPO A cDNA linked to an EPO B cDNA via a linker sequence.

Figure 2 is a diagram showing production of EPO A DNA and sequential elongation of linking DNA strand encoding [gly-gly-gly-gly-ser], using PCR.

Figure 3 is a diagram showing production of EPO B DNA using PCR.

Figure 4 is a diagram showing the end product of each of steps II-IV of Figure 2.

Figure 5 is a diagram showing the end product of Figure 3.

Figure 6 is a diagram showing the restriction digest of pCRBlunt-EPO A^{IV} with Bgl I.

Figure 7 is a diagram showing the restriction digest of pCRBlunt-EPO B^I with Bgl I.

Figure 8 is a diagram showing the restriction digest of pCRBlunt-EPO A^{IV}(-).

Figure 9 is a diagram showing the restriction digest of pCRBlunt-EPO B^I(-).

Figure 10 is a diagram showing the Xho I and BamH I restriction digest of pcDNA3.1(-).

Figure 11 is a diagram showing the restriction digest of pcDNA3.1-EPO-EPO.

-8-

Figure 12 is a schematic representation describing how differences in mRNA and protein structure; and protein function can result from alterations in the 5' and 3' UTR of a gene.

5 Figures 13 A-C depict the nucleotide sequence of the human EPO gene (SEQ ID NO: 1).

Figures 14 A-F depict the nucleic acid sequence of nucleotides 401-624 in the 5' untranslated region of the EPO gene (SEQ ID NO: 2) (Figure 14 A) and five variant 10 sequences (SEQ ID NOS: 3-7) (Figures 14 B-F).

Figures 15 A-E depicts the nucleic acid sequence of nucleotides 2773-2972 in the 3' untranslated region of the EPO gene (SEQ ID NO: 8) (Figure 15 A) and four variant sequences (SEQ ID NOS: 9-12) (Figures 15 B-E).

15 Figures 16A, 16B and 16C depict the nucleic acid sequence (SEQ ID NO: 16) and corresponding amino acid sequence (SEQ ID NO: 17) of the erythropoietin dimer EPO^{wt}-L-EPO^{wt}. A polypeptide linker of 17 amino acid in length (L) links the two EPO protein molecules.

20 Figures 17A, 17B and 17C are graphic representations of the *in vivo* efficacy of the erythropoietin dimer fusion protein (EPO-EPO), erythropoietin monomer (EPO) and culture media from nontransfected COS1 cells (Control) as measured by changes in hematocrits obtained before (Pre) and 7 days 25 after (Post) the administration of a single dose of 300 IU/kg protein.

-9-

DETAILED DESCRIPTION OF THE INVENTION

As used herein, the term fusion protein refers to the fusion of one protein molecule with another protein molecule. In one embodiment the C-terminus of one protein molecule is fused to the N-terminus of another protein molecule. In another embodiment the N-terminus of one protein is linked to the C-terminus of another protein molecule. The fusion proteins of the present invention typically include constructs in which a linker peptide sequence is utilized. The fusion proteins of the present invention have a formula of R_1-R_2 or R_1-L-R_2 , where R_1 and R_2 are substantially similar or identical protein molecules and L is a linker, typically a peptide. In another embodiment of the present invention, R_1 and R_2 can be different proteins. R_1 and R_2 are also referred to as the monomeric subunits of the fusion proteins described herein. The protein molecules are fused to one another in such a manner as to produce a single fusion protein comprised of two or more protein molecules. The fusion protein produced has increased biological activity. In one embodiment of the present invention the protein molecules are EPO.

Fusion protein constructs are named by listing the respective molecules. For example, EPO-L-EPO refers to a fusion protein comprised of two EPO molecules joined by a peptide linker, and EPO-L-EPO-L-EPO refers to a fusion protein comprised of three EPO molecules joined by two peptide linkers.

-10-

The invention also relates to isolated nucleic acid constructs which encode, either independently or together, the protein molecules of the fusion proteins of the present invention. Nucleic acid constructs are defined herein as 5 heteropolymers of nucleic acid sequences. Nucleic acid sequences are meant to refer to chains of nucleotides joined together by phosphodiester bonds to form a nucleic acid heteropolymer. The nucleic acid sequences can be double stranded or single stranded. The nucleic acid 10 sequence can include one or more exons, with or without, as appropriate, introns. Methods to generate nucleic acid constructs encoding the fusion proteins of the invention are standard molecular biological procedures and well known in the art. (See, for example, Aubusel, et al., "Current 15 Protocols in Molecular Biology", John Wiley & Sons, Inc (1997). Alternative combinations or modifications of the nucleic acid constructs according to the present invention would be apparent to the person of skill in the art.

Specifically encompassed are nucleic acid constructs 20 encoding fusion proteins of EPO. For example, a nucleic acid construct encodes an EPO dimer (EPO-L-EPO; Figures 16A-16C SEQ ID NOS: 16 and 17) wherein the nucleic acid encoding the amino terminal portion of the EPO dimer (R1) comprises the 5' untranslated region, a start codon, a pre- 25 protein including the leader sequence, yet lacks a stop codon and is followed by a 17 amino acid peptide linker. The nucleic acid construct encoding the carboxy terminal portion of the EPO dimer (R2) comprises the coding region

-11-

for the mature secreted EPO, a stop codon, and the 3' untranslated region. When expressed in COS1 cells the mRNA encoding the EPO-L-EPO is 2.8 kb in length and the secreted protein dimer is 76 kDa, a molecular weight approximately 5 equivalent to two fully processed and glycosylated EPO protein molecules (37 kDa each) and the 17 amino acid peptide linker (1.8 kDa) (See Example 2). As used herein EPO-L-EPO, EPO-EPO and EPO^{wt}-EPO^{wt} are used equivalently to refer to erythropoietin dimers wherein the monomeric EPO is 10 the wildtype EPO (EPO^{wt}).

The EPO^{wt}-L-EPO^{wt} dimer has increased biological activity compared to monomeric EPO^{wt} when assessed by the standard, art-recognized *in vitro* bioassay of Krystal (*Exp. Hematol.* 11:649-660 (1983)) and by the *in vivo* ability to 15 augment hematocrits following multiple or single injections of dimer (See Example 5; Figures 17A-17C). The EPO^{wt}-EPO^{wt} protein dimer was secreted at significantly higher amounts than EPO^{wt} monomer. Epo^{wt} was secreted from COS1 cells at levels of 6.3 U/ml (0.018 µg/ml), and exhibited a specific 20 activity of 350 U/µg. However, Epo^{wt}/Epo^{wt} was secreted at a level of 151 U/ml (0.150 µg/ml) and had a specific activity of 1007 U/µg, approximately three fold higher than monomeric EPO (See Examples 4 and 5).

Subcutaneous injection of a single dose of EPO^{wt}-EPO^{wt} 25 (300 U/kg) to mice resulted in an elevated hematocrit seven days later, (Example 5, Figures 17A-17C). These *in vivo* and *in vitro* data clearly show the unexpected nature of increased biological activity and enhanced secretion of

-12-

dimeric EPO molecules which can have important implications for *in vitro* production and *in vivo* pharmaceutical compositions.

The nucleic acid constructs of the invention can 5 encode the wildtype protein (e.g., EPO^{wt}) or mutant EPO (e.g., wherein a mutation occurs in the coding region of at least one of the monomeric subunits). The mutation can be, for example, the R103A mutation in EPO wherein the arginine at position 103 is replaced with an alanine. Specifically 10 encompassed by the present invention are EPO^{R103A}-EPO^{wt}, EPO^{wt}-EPO^{R103A}, and EPO^{R103A}-EPO^{R103A} mutant dimers (Examples 7 and 8). A single point mutation in the coding region of EPO results in a dimer with increased biological activity compared to wildtype monomeric EPO. The secretion of the 15 mutant dimers EPO^{R103A}-EPO^{wt}, EPO^{wt}-EPO^{R103A}, and EPO^{R103A}-EPO^{R103A} was unexpectedly enhanced compared to the EPO^{wt}-EPO^{wt} dimer suggesting that the R103A mutation can increase stability of EPO dimer proteins.

The fusion proteins of the present invention can be 20 produced by recombinant DNA technologies using nucleic acid constructs (Examples 1 and 7). The term "recombinant", as used herein, means that a protein is derived from recombinant (e.g., eukaryotic or prokaryotic host cell) expression systems which include, for example, yeast (e.g., 25 *Saccharomyces*), bacteria (such as, *Escherichia* or *Bacillus*), and animal cells including insect or mammalian expression systems. Proteins expressed in most bacterial cultures will be free of glycan. Protein expressed in

-13-

yeast may have a glycosylation pattern different from protein expressed in mammalian cells.

As used herein, the term nucleotide sequence or nucleic acid sequence refers to a heteropolymer of 5 deoxyribonucleotides (DNA), or ribonucleotides (RNA).

Nucleic acid sequences encoding the proteins provided in this invention can be assembled from DNA, either cDNA or genomic DNA, or RNA, and short oligonucleotide linkers to provide a synthetic nucleic acid sequence which is capable 10 of being expressed in a recombinant transcriptional unit.

Homologous nucleic acids, including DNA or RNA, can be detected and/or isolated by hybridization (e.g., under high stringency conditions or moderate stringency conditions).

"Stringency conditions" for hybridization is a term of art 15 which refers to the conditions of temperature and buffer concentration which permit hybridization of a particular nucleic acid to a second nucleic acid in which the first nucleic acid may be perfectly complementary to the second, or the first and second may share some degree of 20 complementarity which is less than perfect. For example, certain high stringency conditions can be used which distinguish perfectly complementary nucleic acids from those of less complementarity. "High stringency conditions" and "moderate stringency conditions" for 25 nucleic acid hybridizations are explained in several technical protocol reference texts, for example, Ausubel, F.M., et al., "Current Protocols in Molecular Biology" (1995), the teachings of which are hereby incorporated by

-14-

reference. The exact conditions which determine the stringency of hybridization depend not only on ionic strength, temperature and the concentration of destabilizing agents such as formamide, but also on factors 5 such as the length of the nucleic acid sequence, base composition, percent mismatch between hybridizing sequences and the frequency of occurrence of subsets of that sequence within other non-identical sequences. Thus, high or moderate stringency conditions could be determined for 10 detecting the various forms of recombinant polypeptides.

By varying hybridization conditions from a level of stringency at which no hybridization occurs to a level at which hybridization is first observed, conditions which will allow a given sequence to hybridize (e.g., 15 selectively) with the sequences, with substantially similar identity in the sample can be determined.

Exemplary conditions are described in Krause, M.H. and Aaronson, S.A., *Methods in Enzymology*, 200:546-556, 1991. Also, "Current Protocols in Molecular Biology" (*supra*), 20 which describes how to determine washing conditions for moderate or low stringency conditions. Washing is the step in which conditions are usually set so as to determine a minimum level of complementarity of the hybrids. Generally, starting from the lowest temperature at which 25 only homologous hybridization occurs, each °C by which the final wash temperature is reduced (holding SSC concentration constant) allows an increase by 1% in the maximum extent of mismatching among the sequences that

-15-

hybridize. Generally, doubling the concentration of SSC results in an increase in T_m of -17°C. Using these guidelines, the washing temperature can be determined for high, moderate or low stringency, depending on the level of 5 mismatch sought. For example, in this invention alterations in the noncoding (5' and 3' untranslated) regions of the gene may necessitate changes in stringency conditions from low to medium to high depending upon the number of nucleotides that are modified that differ from 10 the condition used to detect wild type versions of the gene. Where appropriate the salt concentrations and temperatures will be adjusted accordingly.

The term recombinant expression vector, as used herein, refers to a replicable DNA construct used either to 15 amplify or to express DNA which encodes the fusion proteins of the present invention. The recombinant expression vector includes a transcriptional unit comprising an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, promoters 20 or enhancers; (2) a structural or coding sequence which is transcribed into mRNA and translated into protein; and (3) appropriate transcription and translation initiation and termination sequences. Structural elements intended for use in yeast expression systems preferably include a leader 25 sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader sequence or transport sequence, it may include an N-terminal methionine residue.

-16-

This residue may optionally be subsequently cleaved from the expressed recombinant protein to provide a final product.

A DNA sequence encoding a fusion protein is
5 constructed using recombinant DNA techniques to assemble separate DNA fragments encoding proteins into an appropriate expression vector. For example, the 3' end of a DNA molecule encoding a protein is ligated to the 5' end of a second DNA molecule encoding the same or a
10 substantially similar protein, with the reading frames of the sequences in phase to permit mRNA translation of the sequences into a single biologically active fusion protein. The DNA molecules are joined in tandem, meaning that the DNA molecules are joined in succession, one after the
15 other. The regulatory elements responsible for transcription of DNA into mRNA are retained on the first of the two DNA sequences while binding signals or stop codons, which would prevent read-through to the second DNA sequence, are eliminated. Conversely, regulatory elements
20 are removed from the second DNA sequence while stop codons required to end translation are retained.

As described herein, means are provided for linking protein molecules, preferably via a linker sequence(s). The linker sequence(s) separates the protein molecules by a
25 distance sufficient to ensure that each protein molecule properly folds into its secondary and tertiary structures. Suitable linker sequences (1) adopt a conformation suitable to result in a fusion protein with increased biological

-17-

activity, (2) do not exhibit a propensity for developing an ordered secondary structure which could impair the biological functions of the protein molecules, and (3) have minimal hydrophobic or charged character which could impair 5 the biological functions of the EPO molecules. For example, a suitable linker will produce a fusion protein where interaction of the protein components results in increased biological activity. The linker conformation can be flexible or rigid, depending on the final conformation 10 of the fusion required to result in increased biological activity. An example of a more rigid linker would be a linker with an α -helix that would not allow free rotation of the linked protein components. Typical surface amino acids in flexible protein regions include Glycine (Gly), 15 Asparagine (Asn) and Serine (Ser). Virtually any permutation of amino acid sequences containing Glycine (Gly), Asparagine (Asn) and Serine (Ser) would be expected to satisfy the above criteria for linker sequence. Other near neutral amino acids, such as Threonine (Thr) and 20 Alanine (Ala), may also be used in the linker sequence.

The length of the linker sequence may vary without significantly affecting the biological activity of the fusion protein. Generally, the protein, e.g., EPO, molecules will be separated by a linker sequence having a 25 length of about 10 amino acids to about 20 amino acids, although longer linker sequences may be used, for example, a full-length polypeptide can comprise the linker. In the most preferred aspects of the present invention, the linker

-18-

sequence is about 15 amino acids in length. The linker sequence is incorporated into the fusion protein by well-known methods and as described in Example 1.

In one embodiment, the fusion proteins described
5 herein comprise wild type (e.g., naturally-occurring) proteins with therapeutic activity. As defined herein, therapeutic activity means the ability of a fusion protein, upon administration to a mammal, to alleviate, to any degree, or eliminate the deficiency or condition for which
10 the mammal is being treated. Specifically encompassed by the present invention are cytokines, growth factors, and hormones which include, for example, the particular proteins listed in the following paragraphs followed by the appropriate reference(s). These references as described
15 herein, provide guidance for the production, purification and evaluation of biological activity of the cytokines using standard, routine methods. Nucleic acid sequences coding for the protein molecules of suitable cytokines (e.g., EPO) for making the protein multimers of the present
20 invention are known in the art and can be readily obtained from, for example, the EMBL/GenBank data bases. Each of the references in the following paragraphs is incorporated by reference in its entirety.

INTERFERON- α : Henco, K., et al., *J. Mol. Biol.*, 185:
25 227-260 (1985). Pestka, S., et al., *Ann. Rev. Biochem.*, 56:
727-777 (1987). *Methods in Enzymology*, Pestka, S., (Ed.), Academic Press, New York, NY, 119:3-14 (1986).

-19-

INTERFERON- β : "Human Cytokines: Handbook for Basic and Clinical Research", Aggarwal, B.B., and Guterman, J.U. (Eds.), Blackwell Scientific Publications, Boston, MA (1992).

5 INTERFERON- γ : Gray, P.W., et al., *Nature*, 298:859-863 (1982). Rinderknecht, E., et al., *J. Biol. Chem.*, 259:6790-6797 (1984).

INTERLEUKIN-1: IL-1 α : Furutani, Y., et al., *Nucleic Acids Res.*, 143:167-3179 (1986). IL-1 β : Clark, B.D., et al., *Nucleic Acids Res.* 14:7897-7914 (1986).

10 INTERLEUKIN-2: Fujita et al., 1983. Durand, D.B., et al., *Mol. Cell Biol.*, 8:1715-1724 (1988).

INTERLEUKIN-3: Yang, Y.C., et al., *Cell*, 47:3-10 (1986).

15 INTERLEUKIN-4: Arai, N., et al., *J. Immunol.*, 142:274-282 (1989).

INTERLEUKIN-5: Azuma, C., et al., *Nucleic Acids Res.*, 14:9149-9158 (1986). Yokota, T., et al., *Proc. Natl. Acad. Sci. USA*, 84:7388-7392 (1987).

20 INTERLEUKIN-6: Hirano, T., et al., *Nature*, 324:73-76 (1986). Van Snick, J., et al., *Eur. J. Immunol.*, 18:193-197 (1988).

INTERLEUKIN-7: Goodwin, R.G., et al., *Proc. Natl. Acad. Sci. USA*, 86:302-306 (1989).

25 INTERLEUKIN-8: Kusner, D.J., et al., *Kidney International* 39:1240-1248 (1991).

INTERLEUKIN-9: Renaud, J-C., et al., *J. Immunol.*, 144:4235-4241 (1990). Moeller, J., et al., *J. Immunol.*

-20-

144:4231-4234 (1990). Yang, Y.C., et al., *Blood*, 74:1880-1884 (1989).

INTERLEUKIN-10: Moore, K.W., et al., *Science*, 248:1230-1234 (1990). Fiorentino, D.F., et al., *J. Exp.*

5 *Med.*, 170:2081-2095 (1989).

INTERLEUKIN-11: Paul, S.R., et al., *Proc. Natl. Acad. Sci. USA*, 87:7512-7516 (1990).

INTERLEUKIN-12: Wolf, S.F., et al., *J. Immunol.*, 146:3074-3081 (1991); BLAST Database

10 (www.ncbi.nlm.nih.gov), accession number M65290.

INTERLEUKIN-13: Dolganov, G., *Blood*, 87:3316-3326 (1996).

INTERLEUKIN-14: Ambrus, J.L., et al., *Proc. Natl. Acad. Sci. USA*, 90:6330-6334 (1993).

15 INTERLEUKIN-15: Meazza, R., et al., *Oncogene*, 12:2187-2192 (1996).

INTERLEUKIN-16: Cruikshank, W.W., et al., *Proc. Natl. Acad. Sci. USA*, 91:5109-5113 (1994).

ERYTHROPOIETIN: Jacobs, K., et al., *Nature*, 313:806-20 810 (1985).

COLONY-STIMULATING FACTOR-1: Kawasaki, E.S., et al., *Science*, 230:291-296 (1985). Wong, G.G., et al., *Science*, 235:1504-1508 (1987). Ladner, M.B., et al., *EMBO J.*, 6:2693-2698 (1987). Cerretti, D.P., et al., *Mol. Immunol.*, 25:761-770 (1988). "Colony Stimulating Factors", Dexter, T.M., et al. (Eds.), Marcel Dekker Publishers, New York, NY pp. 155-176 (1990).

-21-

GRANULOCYTE-COLONY-STIMULATING FACTOR: Nagata, S., et al., *Nature*, 319:415-418 (1986). Souza, L.M., et al., *Science*, 232:61-65 (1986).

GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR:

5 Miyataka, S., et al., *EMBO J.*, 4:2561-2568 (1985).

LEUKEMIA INHIBITORY FACTOR: Moureau, J-F., et al., *Nature*, 336:690-692 (1988).

TUMOR NECROSIS FACTOR: Nedwin, G.E., et al., *Nucleic Acids Res.*, 13:6361-6373 (1985).

10 LYMPHOTOXIN: Nedwin, G.E., et al., *J. Cell Biochem.*, 29:171-182 (1985).

PLATELET-DERIVED GROWTH FACTOR: Deuel, T.F., et al., *J. Biol. Chem.*, 256:8896-8899 (1981). "Human Cytokines: Handbook for Basic and Clinical Research", Aggarwal, B.B., 15 and Guttermann, J.U. (Eds.), Blackwell Scientific Publications, Boston, MA (1992).

FIBROBLAST GROWTH FACTORS: Abraham, J.A., et al., *Science*, 233:545-547 (1986a).

VASCULAR ENDOTHELIAL CELL GROWTH FACTOR: Keck, P.J., 20 et al., *Science*, 246:1309-1312 (1989).

EPIDERMAL GROWTH FACTOR: Scott, J., et al., *Science*, 221:236-240 (1983). Gray, A., et al., *Nature*, 303:722-725 (1983).

TRANSFORMING GROWTH FACTOR- β : Deryck, R., et al., 25 *Nature*, 316:701-705 (1985). Scotto, L., et al., *J. Biol. Chem.*, 265:2203-2208 (1990).

TRANSFORMING GROWTH FACTOR- α : Deryck, R., *Cell*, 54:593-595 (1988).

-22-

THROMBOPOIETIN: Sohma, Y., et al., *FEBS Lett.*, 353: 57-61 (1994); BLAST Database (www.ncbi.nlm.nih.gov), accession number D32046.

STEM CELL FACTOR: Williams, D.E., et al., *Cell*, 5 63:167-174 (1990). Copeland, N.G., et al., *Cell*, 63:174-183 (1990). Flanagan, J.G., et al., *Cell*, 63:185-194 (1990). Zsebo, K.M., et al., *Cell*, 63:213-224 (1990). Martin, F.H., et al., *Cell*, 63:203-211 (1990). Zsebo, K.M., et al., *Cell*, 63:195-201 (1990). Huang, E., et al., 10 *Cell*, 63:225-233 (1990). Anderson, D.M., et al., *Cell*, 63:235-243 (1990).

ONCOSTATIN M: Linsley, P.S., et al., *Mol. Cell. Biol.*, 10:1882-1890 (1990). Zarling, J.M., et al., *Proc. Natl. Acad. Sci. USA*, 83:9739-9743 (1986). Malik, N., et 15 al., *Mol. Cell. Biol.*, 9:2847-2853 (1989).

AMPHIREGULIN: Plowman, G.D., et al., *Mol. Cell. Biol.*, 10:1969-1981 (1990). Shoyab, M., et al., *Proc. Natl. Acad. Sci. USA*, 85:6528-6532 (1988).

MULLERIAN-INHIBITING SUBSTANCE: Cate, R.L., et al., 20 *Cell*, 45:685-698 (1986). Wallen, J.W., et al., *Cancer Res.*, 49:2005-2011 (1989). Picard, J-Y., et al., *Proc. Natl. Acad. Sci. USA*, 83:5464-5468 (1986). Coughlin, J.P., et al., *Mol. Cell. Endocrinol.*, 49:75-86 (1987).

B-CELL GROWTH FACTOR: Sharma, S., et al., *Science*, 25 235:1489-1492 (1987).

MACROPHAGE MIGRATION INHIBITORY FACTOR: Weiser, W.Y., et al., *Proc. Natl. Acad. Sci. USA*, 86:7522-7526 (1989).

-23-

ENDOSTATIN: O'Reilly, M.S., et al., *Cell*, 88:277-285 (1997).

ANGIOSTATIN: O'Reilly, M.S., et al., *Cell*, 79:315-328 (1994).

5 Also encompassed by the present invention are fusion proteins comprising biologically active fragments, analogs, mutants, variants or derivatives of the naturally-occurring proteins described herein. Biologically active fragments, derivatives, analogs, variants and mutants of the
10 naturally-occurring proteins are also referred to herein as substantially similar proteins of the naturally-occurring protein. However, the level of biological activity of fragments, analogs, mutants, variants or derivatives of the naturally-occurring protein need not be identical to the
15 activity of the naturally-occurring protein (also referred to herein as the parent protein). For example, a fragment of a cytokine protein may exhibit only 50-80% of the activity of the naturally-occurring cytokine, yet because two or more cytokines, either the same or different, are
20 linked to form a fusion protein, the fusion protein exhibits increased biological activity as compared to a monomer of the naturally-occurring cytokine. Tests to determine biological activity are well-known to those of skill in the art and can include, for example, measuring
25 the extent of hematopoiesis, platelet production, receptor binding, angiogenesis, immunostimulation, or immunosuppression. For example, the biological activity of a mutant of erythropoietin can be measured using *in vitro*

-24-

and *in vivo* assays as described in U.S. Patent Nos. 5,614,184 and 5,580,853. The teachings of which are herein incorporated by reference in their entirety.

As described in detail in Sytkowski et al., (U.S. Patent No. 5,614,184 (1997)) and in Example 4, the biological activity of EPO fusion proteins can be determined using the well-established *in vitro* bioassay of Krystal (*Exp. Hematol.* 11:649-660 (1983)). The Krystal assay measures the effect of EPO on intact mouse spleen cells. EPO fusion protein-stimulated production of red blood cells is then monitored by ^3H -thymidine incorporation and quantitated by competitive radioimmunoassay (RIA) or enzyme linked immunoassay (ELISA). The specific activity of the EPO fusion protein is expressed as a ratio of international units according to the World Health Organization Second International Reference Preparation divided by micrograms of protein determined by RIA or ELISA. As a control the *in vitro* biological activity of EPO monomer is run in parallel with EPO fusion proteins. EPO-EPO dimers had approximately eight-fold higher biological activity compared to monomeric protein.

The biological activity of EPO fusion proteins can also be evaluated using *in vivo* assays according to the method of Sytkowski A.T., et al., (*Proc. Natl. Acad. Sci. USA* 95:1184-1188 (1998)) as described in Example 5. Briefly, EPO multimer (e.g., 300 IU/kg) is injected into mice and hematocrits determined in blood samples obtained before (Pre) or after (Post) treatment. EPO multimer can

-25-

be administered on days 1, 3 and 5; and hematocrits determined on day 8. Additionally, or alternatively, mice can receive a single injection of EPO multimer on day 1 and the hematocrit determined 7 days following the injection or 5 on day 8 of the assay.

As shown in Figures 17A-17C and in Example 5 a single injection of 300 IU/kg of the dimer EPO^{wt}-L-EPO^{wt} results in an increase in the mean hematocrit compared to animals injected with wildtype monomer. Thus, the hematocrit of 10 EPO-EPO dimer treated mice remained elevated at day 8 unlike the monomer treated animals. Therefore, the half-life and *in vivo* activity of dimerized erythropoietin was augmented. These *in vivo* data for fusion proteins described herein are significant in documenting 15 biologically potent fusion proteins with enhanced activity and prolonged half-lives. The observed increase in *in vitro* and *in vivo* bioactivity of EPO-EPO dimers are, unexpectedly significantly greater than activities that would be predicted from two molecules of EPO. Indeed, less 20 frequent, for example, subcutaneous administration of polypeptides in a clinical setting can be therapeutically efficacious.

The present invention also provides fusion proteins with or without associated native-protein glycosylation. 25 Non-glycosylated fusion proteins can be expressed from nucleic acid constructs in host cells, such as *E. coli*, which do not glycosylate protein molecules. Alternatively, or additionally, nucleic acid constructs encoding the

-26-

fusion proteins of the present invention can be selectively modified to encode mutant analogs having inactivated N-glycosylation sites by routine methods such as oligonucleotide synthesis and ligation or site-specific 5 mutagenesis (See Example 6). These analog proteins can be produced in a homogeneous, reduced carbohydrate form in good yield using yeast expression systems. N-glycosylation sites in eukaryotic proteins are characterized by the amino acid triplet Asn-A₁-Z, where A₁ is any amino acid except 10 Proline (Pro), and Z is Serine (Ser) or Threonine (Thr). In this sequence, asparagine provides a side chain amino group for covalent attachment of carbohydrate. Such a site can be eliminated by substituting another amino acid for Asparagine (Asn) or for residue Z, deleting Asparagine 15 (Asn) or Z, or inserting a non-Z amino acid between A₁ and Z, or an amino acid other than Asparagine (Asn) between Asparagine (Asn) and A₁.

Also encompassed by the present invention are fusion proteins comprising protein molecules with at least one or 20 more additional glycosylation sites (e.g., N-linked, or O-linked) than the wildtype protein molecule. The protein molecules can be, for example, novel erythropoiesis stimulating protein molecules, such as NESP, which has an increased circulatory half-life (Egrie, J., et al., *Blood* 25 90:56a (1997); Fürst, I., *Nature Biotechnology* 15:940 (1997)). In the case of NESP, additional N-linked sites can be generated as described herein by, for example, substitution of leucine at position 69, or alanine at

-27-

- position 125 (or both) with an asparagine residue; or, additionally or alternatively, alanine at position 127 with a serine residue. Likewise, additional O-linked glycosylation sites can be produced wherein the alanine at 5 position 123 or position 125 is substituted with a threonine or serine residue. Glycosylation can be further enhanced by placing proline residues at positions -1 and/or +1 relative to the glycosylation sites (e.g., the glycosylation of a threonine residue at position 125 is 10 augmented when proline is located at either position 124 or position 126) (Elliott, S., et al., *Biochemistry* 33:11237 (1994)). It is further envisioned that any combination of the above described glycosylation sites would also be within the scope of the invention.
- 15 Derivatives and analogs can be obtained by mutations of the fusion protein. A derivative or analog, as referred to herein, is a polypeptide comprising an amino acid sequence that shares sequence identity, or similarity, with the full-length sequence of the wild type (or naturally occurring protein), except that the derivative or analog 20 has one or more amino acid sequence differences attributable to a deletion, insertion and/or substitution. Sequences for derivatives or analogs of the protein molecules comprising the fusion proteins of the present 25 invention can be aligned using database search strategies well known in the art including, for example, Basic Local Alignment Search Tool (BLAST) (Altschul, S.F., et al., *J. Mol. Biol.* 215:403-410 (1990)) and FASTA (Pearson, W.R., et

-28-

al., Proc. Natl. Acad. Sci. U.S.A. 85:2444-2448 (1988))
algorithms.

Bioequivalent analogs of proteins can be constructed by, for example, making various substitutions of residues 5 or sequences. For example, cysteine residues can be deleted or replaced with other amino acids to prevent formation of incorrect intramolecular disulfide bridges upon renaturation. Other approaches to mutagenesis involve modification of adjacent dibasic amino acid residues to 10 enhance expression in yeast systems in which KEX2 protease activity is present. Generally, substitutions should be made conservatively; i.e., the most preferred substitute amino acids are those having physicochemical characteristics resembling those of the residue to be 15 replaced. Similarly, when a deletion or insertion strategy is adopted, the potential effect of the deletion or insertion on biological activity should be considered. Due to degeneracy of the genetic code, there can be considerable variation in nucleotide sequences encoding the 20 same amino acid sequence. Therefore, the nucleic acid constructs encoding the fusion proteins of the present invention, bioequivalent analogs or derivatives of the protein molecules comprising the fusion proteins described herein can be altered to produce a codon encoding the same 25 amino acid. For example, the amino acid alanine is encoded by the nucleotide triplet GCA or GCC or GCG or GCU. This can be advantageous for the production of fusion proteins

-29-

by recombinant technologies where a codon is preferred by a selected host cell.

Mutations in nucleotide sequences constructed for expression of analogs must, of course, preserve the reading frame phase of the coding sequences and preferably will not create complementary regions that could hybridize to produce secondary mRNA structures such as loops or hairpins which would adversely affect translation of the mRNA.

Alternatively, mutations could introduce secondary structure which would result in higher translational efficiency. Although a mutation site may be predetermined, it is not necessary that the nature of the mutation *per se* be predetermined. For example, in order to select for optimum characteristics of mutants at a given site, random mutagenesis may be conducted at the target codon and the expressed mutants screened for the desired activity.

Mutations can be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes an analog having the desired amino acid insertion, substitution, or deletion.

Alternatively, oligonucleotide-directed site-specific mutagenesis procedures (see Example 6) can be employed to provide an altered gene having particular codons altered according to the substitution, deletion, or insertion required. Conserved and/or nonconserved amino acids, including amino acids at or distant from the active site of

-30-

the protein molecules comprising the fusion proteins, can be modified. Exemplary methods of making the alterations set forth herein are disclosed by Walder *et al.* (*Gene* 42:133, 1986); Bauer *et al.* (*Gene* 37:73, 1985); Craik 5 (*BioTechniques*, January 1985, 12-19); Smith *et al.* ("Genetic Engineering: Principles and Methods", Plenum Press, 1981); and U.S. Patent Nos. 4,518,584 and 4,737,462 and are incorporated by reference herein. Such techniques are routine, art-recognized and well-known to one of skill. 10 Generally, commercially available kits to make the alterations described herein are available.

The mutations can be in one or more of the protein molecules comprising the fusion protein. Specifically, the present invention encompasses mutants of EPO fusion 15 proteins comprising a R103A mutation in the coding region of EPO wherein the arginine at position 103 is replaced by an alanine in at least one of the EPO domains of the dimer (See Example 7). Such a mutation can lead to increased stability of the mRNA encoding for the mutant dimer fusion 20 protein thereby resulting in increased secretion of the fusion protein providing a useful method for augmenting production yields of fusion proteins using recombinant methods described herein as well as for *in vivo* therapeutics. Other mutations in the EPO protein molecules 25 comprising the fusion proteins of the present invention can also be made. For example, the substitution of the glycine residue at position 101 with another amino acid such as alanine, which results in increased biological activity of

-31-

EPO monomer (Sytkowski et al., U.S. Patent No. 5,614,184 (1997)), could be introduced into EPO protein molecules.

Other EPO mutants which comprise the protein molecules of the fusion proteins of the present invention can be, for 5 example, produced as described by Elliott et al., (*Biochemistry* 33:11237 (1994)). For example, Elliott et al., have shown that biological activity is not altered by site specific mutagenesis within residues 21-44; 52-95; 109-140; and 163-166 of EPO. Thus, fusion proteins 10 comprising EPO mutant protein molecules with these mutations are within the scope of the invention.

Peptidomimetics (molecules which are not protein molecules, but which mimic aspects of their structures to mediate biological activity), that are based upon the 15 fusion proteins (e.g., $\text{EPO}^{\text{wt}}\text{-L-EPO}^{\text{wt}}$, $\text{EPO}^{\text{wt}}\text{-L-EPO}^{\text{R103A}}$, $\text{EPO}^{\text{R103A}}\text{-EPO}^{\text{wt}}$, $\text{EPO}^{\text{R103A}}\text{-EPO}^{\text{R103A}}$) and protein molecules (e.g., EPO) comprising the fusion proteins of the present invention, which have increased biological activity(e.g., increased hematocrit, prolonged protein or mRNA half-life), are also 20 within the scope of the present invention. For example, polysaccharides can be prepared that have the same functional groups as the fusion proteins and protein molecules of the invention, and which interact with target cells or mediate biological activity in a similar manner. 25 Peptidomimetics can be designed, for example, by establishing the three dimensional structure of a protein molecule in the environment in which it is bound or will bind to the target cell.

-32-

The protein molecules of the present invention can comprise naturally-occurring amino acids (e.g., L-amino acids), non-naturally-occurring amino acids (e.g., D-amino acids), and small molecules that biologically mimic the 5 protein molecules such as the protein molecule analogs, derivatives or mimetics described herein. The protein molecules and peptidomimetics of the present invention can be in a linear or cyclic conformation.

The protein molecules and fusion proteins of the 10 present invention can comprise either the 20 naturally occurring amino acids or other synthetic amino acids.

Synthetic amino acids encompassed by the present invention include, for example, naphthylalanine, L-hydroxypropylglycine, L-3,4-dihydroxyphenylalanyl, α -amino acids such as L- α -hydroxylysyl and D- α -methylalanyl, L- α -methyl-alanyl, β amino-acids such as β -analine, and isoquinolyl.

D-amino acids and other non-naturally occurring synthetic amino acids can also be incorporated into the 20 protein molecules and fusion proteins of the present invention. Such other non-naturally occurring synthetic amino acids include those where the naturally occurring side chains of the 20 genetically encoded amino acids (or any L or D amino acid) are replaced with other side chains, 25 for instance with groups such as alkyl, lower alkyl, cyclic alkyl, amide, hydroxy, carboxy, lower alkyl carboxylic acid ester, sulfonic acid, a lower alkyl sulfonic acid ester or a phosphorous acid or ester thereof.

-33-

These peptidomimetics possess biological activity (e.g., stimulate hematopoiesis) lesser than, comparable to or greater than the biological activity of the corresponding protein molecule (e.g., EPO) or fusion 5 protein (e.g., EPO^{wt}-L-EPO^{wt}, EPO^{wt}-L-EPO^{R103A}, EPO^{R103A}-EPO^{wt}, EPO^{R103A}-EPO^{R103A}), but can possess a "biological advantage" over the corresponding protein with respect to one, or more, of the following properties: solubility, stability, and susceptibility to hydrolysis or proteolysis.

10 Methods for preparing peptidomimetics include modifying the N-terminal amino group, the C-terminal carboxyl group, and/or changing one or more of the amino linkages in the peptide to a non-amino linkage. Modifications of peptides to produce peptide mimetics are 15 described in U.S. Patent Nos: 5,643,873 and 5,654,276, the teachings of which are incorporated herein by reference. The protein molecules and fusion proteins can also be cyclic peptide mimetics. Such cyclic test substances can be produced using known laboratory techniques (e.g., as 20 described in U.S. Patent No: 5,654,276, the teachings of which are herein incorporated in their entirety by reference).

These peptidomimetic compounds can be manufactured by art-known and art-recognized methods. Determining an 25 appropriate chemical synthesis route for the peptidomimetics will depend upon the particular protein molecule and fusion protein and is generally readily identified using no more than routine skill.

-34-

For example, when designing a peptidomimetic for a basic amino acid in a protein molecule suitable nitrogen containing groups can include amines, ammoniums, guanidines and amides or phosphoniums; or when designing a 5 peptidomimetic for an acidic amino acid in a protein molecule, a carboxyl, lower alkyl carboxylic acid ester, sulfonic acid, a lower alkyl sulfonic acid ester or a phosphorous acid or ester thereof can be used. The nitrogen of a peptide bond can be substituted with oxygen 10 or sulfur, thereby forming a polyester backbone. Likewise, the carbonyl of the peptide bond can be substituted with a sulfonyl group or sulfonyl group, thereby forming a polyamide. Reverse amides of protein molecules can also be made (e.g., substituting one or more -CONH- groups for a - 15 NHCO- group). In addition, the peptide backbone can be substituted with a polysilane backbone.

In another embodiment, the fusion proteins described herein comprise variant type proteins produced by modifications in 5' and/or 3' noncoding regions of the 20 wildtype gene. Hereinafter, the term recombinant variant protein will be used to describe these molecules. These recombinant variant proteins can have altered biological activity.

Each individual protein that comprises the fusion 25 protein can itself have altered biological activity compared to the activity of the wildtype protein. Altered biological activity is defined herein as activity different from that of the wildtype or recombinant protein. For

-35-

example, the activity of EPO is to regulate the growth and differentiation of red blood cell progenitors. Recombinant EPO variant proteins can have increased activity relative to wildtype EPO to regulate growth and differentiation of 5 red blood cell progenitor cells. Alternatively, the EPO variant proteins containing mutations in the noncoding regions of the gene (e.g., 3' and 5' untranslated regions) can have decreased biological activity relative to the wildtype EPO.

10 Mutations in noncoding regions of the gene (e.g., 5' untranslated regions or UTR) can lead to differences in RNA translation as described, e.g., in Schultz, D.E., et al., *J. Virol.* 70:1041-1049, 1996; Kozak, M., *J. Mol. Biol.* 235:95-110, 1994; and Kozak, M., *J. Biol. Chem.* 266:19867-15 19870, 1991. For example, as described in detail in Example 4, computer modeling can be used to predict differences in RNA secondary structure (e.g., free energy of loops and base pairs) following nucleotide alterations in 3' and 5' UTR of the EPO gene. Although secondary 20 structure changes in EPO RNA, following mutations in the 5' or 3' UTR, are used as the specific example, it is understood that the instant invention described herein can be used to produce any suitable polypeptide variant protein. As used herein, the term mutation refers to any 25 alteration in the nucleic acid sequence encoding a polypeptide (e.g., a point mutation; the addition, deletion and/or substitution of one or more nucleotides).

-36-

Secondary structure has been shown to be a critical component in determining the rates of translation efficiency of several proteins (Bettany, A.J., et al., *J. Biol. Chem.* 267:16531-16537, 1992; Kozak, M., *J. Mol. Biol.* 5 235:95-110, 1994). By implication, altered rates of translation can affect posttranslational modifications, for example, glycosylation patterns, and, thus, proper folding of the resulting protein leading to changes in the chemistry, structure and function of the protein. The 10 recombinant variant proteins described herein are unique in that they are composed of fusion proteins produced by mutations in 5' and 3' untranslated (noncoding) regions of the gene.

The present invention also provides recombinant 15 expression vectors which include synthetic or cDNA-derived DNA fragments encoding fusion proteins comprising DNA encoding two or more linked proteins operably linked to suitable transcriptional or translational regulatory elements derived from mammalian, microbial, viral or insect 20 genes. Such regulatory elements include a transcriptional promoter, an optional operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding sites, and sequences which control the termination of transcription and translation, as described in detail 25 below. The ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants may additionally be incorporated. Operably linked indicates that components

are linked in such a manner that expression of the DNA encoding a fusion protein is controlled by the regulatory elements. Generally, operably linked means contiguous.

Transformed host cells are cells into which fusion 5 protein vectors have been introduced by infectious or non-infectious methods. Transformed host cells ordinarily express the desired fusion protein, but host cells transformed for purposes of cloning or amplifying DNA do not need to express the protein. In eukaryotic cells, 10 expressed fusion protein will generally be secreted into the culture supernatant. In prokaryotic cells, the fusion proteins may be expressed within the periplasmic space or as insoluble inclusion bodies. Suitable host cells for expression of fusion protein include prokaryotes, yeast or 15 higher eukaryotic cells under the control of appropriate promoters. Prokaryotes include gram negative or gram positive organisms, for example *E. coli*. Higher eukaryotic cells include established cell lines of mammalian origin as described below. Cell-free translation systems could also 20 be employed to produce fusion protein using RNAs derived from the DNA constructs of the present invention.

Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are described by Pouwels et al. ("Cloning Vectors: A Laboratory 25 Manual", Elsevier, NY, 1985); Sambrook et al., "Molecular Cloning: A Laboratory Manual", Second Edition (1989); and Ausubel, F.M. et al., "Current Protocols in Molecular Biology", John Wiley & Sons, Inc. (1997), which are

-38-

incorporated herein in their entirety by reference. Such techniques would be familiar to one of skill in the art.

Prokaryotic expression vectors generally comprise one or more phenotypic selection markers, for example a gene 5 encoding proteins conferring antibiotic resistance or supplying an autotrophic requirement, and an origin of replication recognized by the host to ensure amplification within the host. Suitable prokaryotic hosts for transformation include *E. coli*, *Bacillus subtilis*, 10 *Salmonella typhimurium*, and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, although others may also be employed as a matter of choice.

Useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of 15 replication derived from commercially available plasmids comprising genetic elements of the well-known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and pGEM1 (Promega Biotech, Madison, WI). 20 These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed. *E. coli* is typically transformed using derivatives of pBR322, a plasmid derived from an *E. coli* species (Bolivar et al., Gene 2:95, 1977). pBR322 contains 25 genes for ampicillin and tetracycline resistance and thus provides simple means for identifying transformed cells.

Promoters commonly used in recombinant microbial expression vectors include the bla^ctamase

-39-

(penicillinase) and lactose promoter system (Chang et al., *Nature* 275:615, 1978; and Goeddel et al., *Nature* 281:544, 1979), the tryptophan (*trp*) promoter system (Goeddel et al., *Nucleic Acids Res.* 8:4057, 1980) and tac promoter
5 (Sambrook, et al., "Molecular Cloning: A Laboratory Manual", 1989).

Recombinant fusion proteins may also be expressed in yeast hosts, preferably from the *Saccharomyces* species, such as *S. cerevisiae*. Yeast of other genera such as
10 *Pichia* or *Kluyveromyces* may also be employed. Yeast vectors will generally contain an origin of replication from a yeast plasmid or an autonomously replicating sequence (ARS), promoter, DNA encoding the fusion protein, sequences for polyadenylation and transcription termination
15 and a selection gene. Preferably, yeast vectors will include an origin of replication and selectable marker permitting transformation of both yeast and *E. coli*, e.g., the ampicillin resistance gene of *E. coli* and *S. cerevisiae* *trp1* gene, which provides a selection marker for a mutant
20 strain of yeast lacking the ability to grow in tryptophan, and a promoter derived from a highly expressed yeast gene to induce transcription of a structural sequence downstream. The presence of the *trp1* lesion in the yeast host cell genome then provides an effective environment for
25 detecting transformation by growth in the absence of tryptophan.

Suitable promoter sequences in yeast vectors include the promoters for metallothionein, 3-phosphoglycerate

-40-

kinase (Hitzeman, et al., *J. Biol. Chem.* 255:2073, 1980) or other glycolytic enzymes (Hess, et al., *J. Adv. Enzyme Reg.* 7:149, 1968; and Holland, et al., *Biochem.* 17:4900, 1978), such as enolase, glyceraldehyde-3-phosphate dehydrogenase,
5 hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triose-phosphate isomerase, phosphoglucose isomerase, and glucokinase. Suitable vectors and promoters for use in yeast expression are further described in R.
10 Hitzeman, et al., EPA 73,657.

Preferred yeast vectors can be assembled using DNA sequences from pBR322 for selection and replication in *E. coli* (Amp gene and origin of replication) and yeast DNA sequences including a glucose-repressible ADH2 promoter and
15 α-factor leader, which directs secretion of heterologous proteins, can be inserted between the promoter and the structural gene to be expressed (Kurjan, et al., *Cell* 30:933, 1982; and Bitter, et al., *Proc. Natl. Acad. Sci. USA* 81:5330, 1984). The leader sequence may be modified to
20 contain, near its 3' end, one or more useful restriction sites to facilitate fusion of the leader sequence to foreign genes.

Suitable yeast transformation protocols are known to those of skill in the art; an exemplary technique is
25 described by Hinnen, et al., *Proc. Natl. Acad. Sci. USA* 75:1929, 1978, selecting for Trp⁺ transformants in a selective medium consisting of 0.67% yeast nitrogen base,

-41-

0.5% casamino acids, 2% glucose, 10 µg/ml adenine and 20 µg/ml uracil.

Host strains transformed by vectors comprising the ADH2 promoter may be grown for expression in a rich medium
5 consisting of 1% yeast extract 2% peptone, and 1% glucose supplemented with 80 µg/ml adenine and 80 µg/ml uracil.

Derepression of the ADH2 promoter occurs upon exhaustion of medium glucose. Crude yeast supernatants are harvested by filtration and held at 4°C. prior to further purification.

10 Various mammalian or insect cell culture systems can be employed to express recombinant protein. Baculovirus systems for production of heterologous proteins in insect cells are reviewed by Luckow and Summers, *Bio/Technology* 6:47, 1988.

15 Examples of suitable mammalian host cell lines include the COS-7 lines of monkey kidney cells, described by Gluzman (*Cell* 23:175, 1981), and other cell lines capable of expressing an appropriate vector including, for example, L cells, C127, 3T3, Chinese Hamster Ovary (CHO), HeLa and
20 BHK cell lines. Mammalian expression vectors may comprise non-transcribed elements such as an origin of replication, a suitable promoter and enhancer linked to the gene to be expressed, and other 5' or 3' flanking nontranscribed sequences, and 5' to 3' nontranslated sequences, such as
25 necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, and transcriptional termination sequences.

-42-

The variant nucleic acid molecules encoding, for example, recombinant polypeptide variant proteins created by modifying the 3' and/or 5' UTR of the polypeptide gene, would also preferably contain regulatory sequences.

5 Regulatory sequences include all cis-acting elements that control transcription and regulation such as, promoter sequences, enhancers, ribosomal binding sites, and transcription binding sites. Selection of the promoter will generally depend upon the desired route for expressing
10 the protein. For example, where the protein is to be expressed in a recombinant eukaryotic or prokaryotic cell, the selected promoter is recognized by the host cell. A suitable promoter which can be used can include the native promoter for the binding moiety which appears first in the
15 construct.

The elements which comprise the nucleic acid molecule can be isolated from nature, modified from native sequences or manufactured *de novo*, as described, for example, in the above-referenced texts. The elements can then be isolated
20 and fused together by methods known in the art, such as exploiting and manufacturing compatible cloning or restriction sites.

The nucleic acid molecules can be inserted into a construct which can, optionally, replicate and/or integrate
25 into a recombinant host cell, by known methods which may vary depending upon the form of the recombinant polypeptide which is expressed. The host cell can be a eukaryotic or prokaryotic cell and includes, for example, pichia

-43-

expression systems, yeast (such as, *Saccharomyces*), bacteria (such as, *Escherichia* or *Bacillus*), animal cells or tissue, including insect (such as, *Spodoptera frugiperda*) or mammalian cells (such as, somatic or embryonic human 5 cells, Chinese hamster ovary cells, HeLa cells, human 293 cells, monkey kidney COS-7 cells, baby hamster kidney BHK cells, C127 cells, etc.). The selection of the host cell governs the posttranslational modifications that may occur. For instance, glycoproteins could be expressed in 10 mammalian, insect, or yeast cells whereas nonglycosylated proteins could be expressed in bacteria. In addition, the selection of the appropriate host cell may differ when expressing recombinant polypeptide variants manufactured by mutations in the noncoding regions of the gene. (Schultz, 15 et al., *J. Virol.* 70:1041-1049, 1996).

The nucleic acid molecule can be incorporated or inserted into the host cell by known methods. Examples of suitable methods of transfecting or transforming cells include calcium phosphate precipitation, electroporation, 20 microinjection, infection, lipofection and direct uptake. Methods for preparing such recombinant host cells are described in more detail in several technical books, for example, Sambrook, et al., "Molecular Cloning: A Laboratory Manual," (1989) and Ausubel, et al. "Current 25 Protocols in Molecular Biology," (1995).

The host cells are then maintained under suitable conditions for expressing and recovering the recombinant polypeptide. Generally, the cells are maintained in a

-44-

suitable buffer and/or growth medium or nutrient source for growth of the cells and expression of the gene product(s). The growth media are generally known in the art and include sources of carbon, nitrogen and sulfur. Examples include
5 Dulbeccos modified Eagles media (DMEM), RPMI-1640, M199 and Grace's insect media. The selection of a buffer is not critical to the invention. The pH which can be selected is generally one tolerated by or optimal for growth for the host cell.

10 The cell is maintained under a suitable temperature and atmosphere. For example, an aerobic host cell is maintained under aerobic atmospheric conditions or other suitable conditions for growth. The temperature should also be selected so that the host cell tolerates the
15 process and can be, for example, between about 27°C and 40°C.

The transcriptional and translational control sequences in expression vectors to be used in transforming vertebrate cells may be provided by viral sources. For
20 example, commonly used promoters and enhancers are derived from Polyoma, Adenovirus 2, Simian Virus 40 (SV40), and human cytomegalovirus. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early and late promoter, enhancer, splice, and polyadenylation sites may
25 be used to provide the other genetic elements required for expression of a heterologous DNA sequence. The early and late promoters are particularly useful because both are obtained easily from the virus as a fragment which also

-45-

contains the SV40 viral origin or replication (Fiers, et al., *Nature* 273:113, 1978). Smaller or larger SV40 fragments may also be used, provided the approximately 250 bp sequence extending from the Hind III site toward the 5 BglII site located in the viral origin or replication is included. Exemplary vectors can be constructed as disclosed by Okayama and Berg (*Mol. Cell. Biol.* 3:280, 1983).

Preferred eukaryotic vectors for expression of 10 mammalian DNA include pIXY321 and pIXY344, both of which are yeast expression vectors derived from pBC102.K22 (ATCC 67,255) and contain DNA sequences from pBR322 for selection and replication in *E. coli* (Apr gene and origin of replication) and yeast.

15 Purified mammalian fusion proteins or analogs are prepared by culturing suitable host/vector systems to express the recombinant translation products of the DNAs of the present invention, which are then purified from culture media or cell extracts. For example, supernatants from 20 systems which secrete recombinant protein into culture media can be first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. Following the concentration step, the concentrate can be 25 applied to a suitable purification matrix.

The recombinant molecules produced by the processes described herein, including those manufactured by modifications in the 3' and 5' UTR, can be isolated and

-46-

purified by known means. Examples of suitable purification and isolation processes are generally known in the art and include, but are not limited to, ammonium sulfate precipitation, dialysis, electrophoresis, ultrafiltration,
5 microfiltration, gel filtration, ion exchange or immunoaffinity chromatography. In addition, one or more reverse phase high performance liquid chromatography (RP-HPLC) media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify a
10 fusion protein composition. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a homogenous recombinant protein.

Recombinant protein produced in bacterial culture is usually isolated by initial extraction from cell pellets,
15 followed by one or more concentration, salting-out, aqueous ion exchange or size exclusion chromatography steps. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps. Microbial cells employed in expression of recombinant fusion proteins can
20 be disrupted by any convenient method, including freezethaw cycling, sonication, mechanical disruption, or use of cell lysing agents.

Fermentation of yeast which express fusion proteins as a secreted protein greatly simplifies purification.
25 Secreted recombinant protein resulting from a large scale fermentation can be purified by methods analogous to those disclosed by Urdal, et al., (*J. Chromatog.* 296:171, 1984).

-47-

- Fusion protein synthesized in recombinant culture is characterized by the presence of non-human cell components, including proteins, in amount and of a character which depend upon the purification steps taken to recover the
- 5 fusion protein from the culture. These components ordinarily will be of yeast, prokaryotic or non-human higher eukaryotic origin and preferably are present in innocuous contaminant quantities, on the order of less than about 5 percent by scanning densitometry or chromatography.
- 10 Further, recombinant cell culture enables the production of the fusion protein free of proteins which may be normally associated with EPO as they are found in nature in their respective species of origin, e.g., in cells, cell exudates or body fluids.
- 15 The present invention further relates to pharmaceutical compositions comprising a fusion protein and a physiologically-compatible carrier. Such carriers are well-known, routine and described in U.S. Patent No. 5,580,853, the teachings of which are herein incorporated
- 20 by reference in their entirety. Pharmaceutical compositions suitable for administration comprise the fusion protein in an effective amount and a physiologically acceptable carrier.
- An effective amount, as used herein, is defined as
- 25 that quantity which alleviates, to any degree, or eliminates the condition for which the mammal is being treated.

-48-

The carriers will be non-toxic to recipients at the dosages and concentrations employed. The formulation used will vary according to the route of administration selected (e.g., solution, emulsion, capsule). For solutions or
5 emulsions, suitable carriers include, for example, aqueous or alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles can include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed
10 oils. Intravenous vehicles can include various additives, preservatives, or fluid, nutrient or electrolyte replenishers. See, generally, "*Remington's Pharmaceutical Science*", 16th Edition, Mack, Ed. (1980). For inhalation, the compound can be solubilized and loaded into a suitable
15 dispenser for administration (e.g., an atomizer, nebulizer or pressurized aerosol dispenser). Fusion proteins can be administered individually, together or in combination with other drugs or agents (e.g., other chemotherapeutic agents, immune system enhancers).
20 Fusion protein compositions can be used to enhance proliferation, differentiation and functional activation of hematopoietic progenitor cells, such as bone marrow cells. Fusion protein compositions can also be used in the treatment of cancers or cellular growth deficiencies.
25 Specifically, compositions containing the fusion protein may be used to increase peripheral blood leukocyte numbers and increase circulating granulocyte counts in myelosuppressed patients. To achieve this result, a

-49-

therapeutically effective quantity of a fusion protein composition is administered to a mammal, preferably a human, in association with a pharmaceutical carrier or diluent.

5 The recombinant polypeptide variant proteins of the invention can be used as therapeutic for delivery to individuals having diseases or conditions that are associated with deficiencies or abnormalities of the proteins described herein. The retention and/or deletion
10 of nucleotides in untranslated regions of the polypeptide gene can produce heterologous therapeutic proteins. Heterologous proteins are herein defined as proteins which does not exist in nature and exhibit a range of therapeutic effects.

15 Recombinant polypeptides with therapeutic value are known in the art. Examples include the recombinant EPO described in Lin (U.S. Patent No. 4,703,008); Sytkowski et al., (U.S. Patent No. 5,614,184); Sytkowski (U.S. Patent No. 5,580,853); and Powell (U.S. Patent No. 5,688,679); the
20 contents of which are incorporated herein by reference. Therapeutic advantages of recombinant EPO include, for example, an increase in hematocrit and specific activity of the recombinant protein. A recombinant EPO protein molecule with increased biological activity can be
25 generated by substitution of glycine at position 101 with another amino acid residues such as alanine (Sytkowski et al., U.S. Patent No. 5,614,184 (1997)). These references can be used to guide one of skill in the art in the

-50-

manufacturing of nucleic acid constructs encoding protein molecules which comprise the fusion proteins of the invention.

For example, the recombinant EPO variant proteins described herein can be employed in any method where EPO would be effective, and in particular in methods where other man-made EPO proteins have not produced any clinically beneficial effect (e.g., increasing red blood cells in an anemic patient). The mode of EPO administration to patients is preferably at the location of the target cells. As such, the administration can be by injection. Other modes of administration (parenteral, mucosal, systemic, implant, intraperitoneal, etc.) are generally known in the art and, for EPO, can be determined, for example, as described in U.S. Patent No. 5,614,184. The recombinant EPO proteins can, preferably, be administered in a pharmaceutically acceptable carrier, such as saline, sterile water, Ringer's solution, and isotonic sodium chloride solution.

The activity of polypeptide variant proteins can be tested, for example, in pharmacological differences. Accordingly, the activity of the recombinant EPOs could be evaluated therapeutically. For example, pharmacological differences in the secreted and purified EPO manufactured by the disclosed method compared to other man-made or naturally occurring EPOs can include:

1. An increase or decrease in the potency when administered to patients in human clinical

-51-

trials. The difference can be in the required initial dose as well as maintenance doses. A relative potency factor can be evaluated for the recombinant EPO variant proteins.

- 5 2. A reduction or increase in potential side effects in patients may reflect altered activities of the EPO variant proteins. For example, differences can be manifested as an increase or decrease in blood pressure which can be of extraordinary significance in designing treatment regimens for certain high risk patients like dialysis patients who are, in any case, severely ill.
- 10 3. A difference in the time lag between the effect of increasing red blood cells in the patient's serum after administration of the EPO variants. This time-lag has the consequence that the desired therapeutic effect is either accelerated or delayed significantly compared to other forms of recombinant EPO. A decrease in the time lag would be a desirable therapeutic effect by resulting in a faster benefit to the patient.
- 15 4. The ability of a patient to tolerate one form of EPO and not another. If a patient can not tolerate one form of an EPO variant over another, this noncompatibility can indicate therapeutic differences which in turn can reflect structural, biochemical and biological modifications in the various forms of recombinant EPO.
- 20
- 25

-52-

5. An increase in the circulating half-life of EPO in patients which can result in less frequent injections or smaller doses of EPO having to be administered. A prolonged half-life would not only be therapeutically beneficial, but also diminish health care costs in the treatment of chronically ill patients.

Thus, differences in the pharmaceutical characteristics of recombinant polypeptide variant proteins 10 can result in variations in therapeutic effects (e.g., for EPO variants, the production of reticulocytes and red blood cells and an increase in hemoglobin synthesis and iron uptake). For example, a difference in the inherent potency which would result in lower bioloads inflicted on 15 the patient's body by administering an EPO protein which leads to an absence or drastic lowering of side effects (which may endanger the patient's life or make it impossible to administer one form of EPO) is particularly important in high risk patients (e.g., patients with kidney 20 disorders) who are at high risk for hypertension, myocardial infarct or stroke.

Thus, retention, deletion, point mutation or substitution in the 5' and/or 3' UTR sequences of a recombinant EPO gene fragment can ultimately influence the 25 final structure and chemistry of a protein expressed by a host cell transfected with that gene fragment. As a consequence the resulting expressed protein can exhibit

-53-

varying biological parameters which can be assessed using bioassays and in therapeutics.

The present invention will now be further illustrated by the following exemplification, which is not meant to be 5 limiting in any way.

EXAMPLE 1

CONSTRUCTION OF THE EPO-EPO DIMER

An EPO-EPO fusion protein (Figures 16A-16C; SEQ ID NOS: 16 and 17) was constructed by linking two strands of 10 EPO cDNA with a DNA strand encoding the following polypeptide: AGGGGSGGGSGGGST (SEQ ID NO: 18) (Figure 1). The nucleotide sequence of wild type erythropoietin is described in from Jacobs, K., et al., *Nature* 323:806, 1985, which is herein incorporated by 15 reference in its entirety. The linking DNA strand was sequentially lengthened to the proposed length by using psv2-EPO (Figure 2) as template and 3' primers with appropriately extended 3' ends (Figure 2). The initial preceding EPO DNA strand (Figure 4) contains 10 nucleotides 20 in the 5' untranslated region, a leader sequence (Jacobs, K., et al., *Nature* 323:806, 1985), an EPO cDNA coding sequence, and no STOP codon. Additional nucleotides attached to the 3' end were: GCCGGCGGTGGTGGATCTGG (SEQ ID NO: 19)... The EPO DNA strand after the linker (EPO B DNA; 25 Figure 5) contains no leader sequence but has a STOP codon and 17 nucleotides in the 3' untranslated region. Half a NaeI restriction site was designed into the 3' end of EPO A

-54-

DNA and half a ScaI restriction site into the 5' end of EPO B DNA.

EPO A (Figure 2) and EPO B (Figure 3) DNA were produced by the using the Polymerase Chain Reaction (PCR) 5 and a human EPO cDNA plasmid, psv2-EPO (Chern, Y.J., et al., *Eur J Biochem* 202:225, 1991) as template.

Primers used to produce EPO A are as follows: 5'-
AGGCGCGGAGATGGGGGTGCAC (SEQ ID NO: 20) (EpA 5'),
3'-CCAGATCCACCACCGCCGGCTCTGTCCCCTGTCCTGCAGG (SEQ ID NO: 21)
10 (EpA3-3), 3'-CGCCACCGGATCCACCGCCACAGATCCACCACCGCCGGC (SEQ
ID NO: 22) (EpA3-4), and 3'-
TGGTGGGGCAGTACTGCCGCCGCCACCGGATCCACCGCC (SEQ ID NO: 23)
(EpA3-5).

Primers used to produce EPO B are as follows:
15 5'-GCGGCAGTACTGCCACCACGCCTCATCTGTGACAGC (SEQ ID NO: 24)
(EpB 5-1) and 3'-CAGGTGGACACACCTGGTCATC (SEQ ID NO: 25)
(EpB 3').

PCR reactions (50 µl) contained the following components: 0.5 µM of 5' primer or 3' primer; 10 ng psv2-
20 EPO; 200 µM of dATP, dCTP, dGTP, or dTTP; 20 mM Tris-HCl
(pH 8.0); 2 mM MgCl₂; 10 mM KCl; 6 mM (NH₄)₂SO₄; 0.1% Triton X-100; 10 µg/ml nuclease-free BSA; and 2.5 U Pfu DNA
Polymerase (Stratagene). The reactions were overlaid with mineral oil (50 µl; Molecular Biology Grade, Sigma) and
25 subjected to 25 cycles of 94°C for 1 min (denaturation), of 52°C for 1 min (annealing) and of 72°C for 1 min
(extension) in a Perkin Elmer DNA Thermal Cycler 480.

-55-

Next, the DNA sequences of the PCR products were determined. First, the PCR products were purified from a 1% agarose gel using the QIAQUICK™ Gel Extraction Kit. They were then ligated to pCR-blunt, in which the reactions 5 contained an insert to vector molar ratio of 10 to 1. The ligation reactions (10 µl) contained the gel-purified PCR products, 25 ng of PCR-blunt, 1X ligation buffer and 4 U of T4 DNA ligase (ZERO BLUNT™ PCR Cloning Kit, Invitrogen). Incubations were carried out for 1 hour at 16°C.

10 Cells used for expression were TOP 10™ Competent Cells (Invitrogen) and were transformed according to procedure established by Invitrogen: 2 µl of β-mercaptoethanol was added to the cells on ice, mixed by gentle swirling with a pipette tip, followed by 2 µl of the 15 ligation described in the preceding paragraph. This mixture was then incubated on ice for 30 min, followed by exactly 45 seconds at 42°C. The vial was then placed on ice for 2 min. Pre-warmed (37°C) SOC medium (250 µl) containing 2% tryptone, 0.5% yeast extract, 10mM NaCl, 2.5 20 mM KCl, 10 mM MgCl₂, 10 mM MgSO₄, and 20 mM glucose was added and the cells shaken for 1 hr at 37°C. Fifty µl of a 1:5 dilution of transformed cells were plated on LB (Miller's modification, Sigma) agar plates containing 50 µg/ml kanamycin. The plates were incubated at 37°C 25 overnight. Colonies were plucked and 2.5 ml LB containing 50 µg/ml kanamycin were inoculated with these colonies. Plasmid DNA were prepared from the overnight cultures using Promega's WIZARD PLUS MINIPREPS™ DNA Purification System.

-56-

Clones were analyzed by restriction digest fragment analysis.

The pCRBlunt-EPO A and pCRBlunt-EPO B DNA clones were digested with BglI, which gave unique-sized fragments for a 5 correctly inserted DNA and an insert oriented in the reverse direction (Figures 6 and 7). Clones with inserts in the reverse direction were chosen and larger amounts (from 100 ml of LB/50 µg/ml kanamycin) of DNA plasmids prepared using Promega's WIZARD PLUS MAXIPREPS™ DNA 10 purification system. Clones with inserts in the "forward" direction would also have produced the proposed EPO-EPO DNA.

EPO A DNA was linked to EPO B DNA using the procedure described as follows. pCRBlunt-EPO A(-) was digested with 15 Sca I and Xho I and the 677 bp fragment gel purified (Figure 8). pCRBlunt-EPO B(-) was digested with BamHI and ScaI and the 557 bp fragment gel purified (Figure 9). The EPO A 677 bp fragment was then ligated to the EPO B 557 bp fragment in a 1:1 molar ratio of EPO A 677 bp fragment to 20 EPO B 557 bp fragment. Ligations were carried out overnight at 16°C. The ligated EPO A/EPO B DNA fragments were purified using QIAQUICK™ Gel Extraction Kit then ligated to pcDNA2.1(-) which had previously been digested with XhoI and BamHI and gel purified (Figure 10). The 25 ligation reaction contained a 5:1 molar ratio of DNA insert to pcDNA3.1(-). The incubation was carried out overnight at 16°C. Clones were picked from ampicillin-resistant colonies by restriction digest analysis (Figure 11),

-57-

produced in microgram quantities, and used to transfect COS1 cells.

EXAMPLE 2

TRANSIENT EXPRESSION OF EPO DIMER IN COS1 CELLS

- 5 COS1 cells were grown to 70% confluence in Dulbecco's Modified Eagle Medium, high glucose (4.5 g/L; Gibco), 10% fetal bovine serum (Hyclone) in the presence of 100 U penicillin, 100 µg streptomycin, 250 ng Fungizone per ml of tissue culture medium (antibiotic-antimycotic cocktail from 10 Gibco) at 37°C and 10% CO₂. The cells were harvested by trypsinizing using 0.05% trypsin, 0.53 mM EDTA (Gibco) and washing twice with phosphate buffered saline (PBS)/6 mM glucose solution. Cells were suspended in the above PBS/glucose buffer to a concentration of 2 × 10⁶ cells/ml.
- 15 0.5 ml of cells were placed in electroporation cuvettes (0.4 cm gap, Bio-Rad) and 10 µg of pcDNA/EPO-EPO added. The cells were electroporated under the following conditions: voltage = 0.3 kV, field strength = 0.75 kV/cm, capacitor = 250 µF, and resistor = none (Pulse controller 20 set at Ω). Cells were plated in 30 ml of pre-warmed DMEM, high glucose, 10% FBS and incubated for 72 h at 37°C and 10% CO₂. The controls used were 10 µg of pcDNA-EPO and 10 µg of pcDNA 3.1(-). Transfected and non-transfected cells were cultured for 3 days before analysis.
- 25 Total RNA from transiently transfected COS1 cells was prepared using TRIZOL Reagent (GibcoBRL) according to the manufacturer's protocol. Total cellular RNA was separated

-58-

on 1.2% agarose gels containing 5.5% formaldehyde and transferred to a GeneScreen Plus filter. The filter was probed with a digoxigenin-dUTP Boehringer Mannheim according to the procedure described by the manufacturer.

- 5 The EPO-L-EPO fusion protein was encoded by a transcript of approximately 2.8 kb in length. The relative amount of EPO-L-EPO transcript, as assessed by Northern blot analysis, was approximately equivalent to that observed for EPO monomer. Since the secretion of EPO-L-EPO protein was
10 at least eight fold higher than EPO (See Examples 3 and 4), it is likely that the EPO-L-EPO protein dimer is considerably more stable during synthesis than the EPO monomer.

The conditioned media from transfected and
15 nontransfected cells were collected, centrifuged at 13,800 x g for 10 min at 4°C. Aliquots (1 ml) of each conditioned media were dialyzed against Minimum Essential Medium α overnight with 3 changes of medium. The dialyzed samples were assayed for the determination of EPO protein
20 concentrations and used for evaluating *in vitro* and *in vivo* EPO activity.

EXAMPLE 3

EPO PROTEIN DETERMINATION IN COS1 CELL CULTURE MEDIUM

EPO monomer and EPO-L-EPO fusion protein secreted by
25 transfected COS1 cells were detected by Western blotting and Enzyme-Linked Immunoabsorbant Assay (ELISA) in dialyzed conditioned culture media from transfected COS1 cells.

Proteins present in dialyzed samples were separated by SDS-PAGE and electrophoretically transferred to 0.45 µm nitrocellulose membranes in a buffer containing 25 mM Tris-HCl, 192 mM glycine, 10% methanol. Membranes were then
5 briefly rinsed twice with distilled water and incubated overnight at 4°C in 20 mM Tris-HCl, 0.5 M NaCl, 0.5% Tween-20 (TBST), 10% nonfat dry milk, pH 7.5. The membranes were rinsed twice with TBST, washed once with TBST for 15 min and twice for 5 min each. The membranes were then
10 incubated for 1 hr at 23°C with anti-erythropoietin monoclonal antibody AE-7A5 (Genzyme, Corp, Cambridge, MA) at a concentration of 0.7 µg/ml in TBST containing 5% nonfat dry milk. Rinsing and washing were performed as described above, followed by incubation for 1 hr at 23°C
15 with a horse-radish peroxidase conjugated goat anti-mouse IgG (Cappel) diluted 1:1000 in TBST containing 5% nonfat dry milk. Rinsing and washing were again performed as described above except that two additional TBST washes (5 min each) were performed. Antigen (EPO)-antibody complexes
20 were visualized by chemiluminescence detection using an Amersham ECL kit. The EPO-L-EPO dimer was secreted from COS1 cells as a single protein band with a molecular weight of 76 kDa. The molecular weight of the secreted EPO dimer is approximately equivalent to the molecular weight of two
25 fully processed and glycosylated EPO monomers (36 kDa) and the polypeptide linker (1.8 kDa). Therefore, the dimer consists of two complete, mature and fully processed EPO protein molecules.

-60-

An EPO ELISA assay (Genzyme Corp., Cambridge, MA) was used to determine the amount of EPO monomer or dimer present in conditioned media of transfected COS1 cells. The standard curve was calculated using recombinant 5 monomeric EPO (rhuEPO) according to routine methods described previously. See, for example, Sytkowski et al., U.S. Patent No. 5,614,184 (1997) and Sytkowski et al., *Proc. Natl. Acad. Sci. USA* 95:1184-1188 (1998).

The EPO-L-EPO fusion protein dimer was secreted from 10 COS1 cells at a concentration of 0.15 µg/ml which is approximately eight-fold higher than the amount EPO monomeric protein secreted by COS1 cells (0.018 µg/ml) (See Table 1, Example 4). As discussed above, it is possible that the protein dimer is considerably more stable than the 15 monomer protein molecule during protein synthesis. Such a property can be advantageous for *in vitro* production and *in vivo* therapeutic purposes.

EXAMPLE 4

IN VITRO BIOACTIVITY OF EPO DIMER

20 The *in vitro* activity of EPO-L-EPO dimer protein was determined according to the method of Krystal (*Exp. Hematol.* 11:649-660 (1983)) as described herein and as described in U.S. Patent No. 5,580,853, which is herein incorporated by reference in its entirety. As previously 25 discussed the Krystal bioassay measures the effect of EPO monomer or EPO fusion proteins on erythroid cell proliferation using intact mouse spleenic erythroid cells.

-61-

Recombinant EPO was used to generate the standard curve against the World Health Organization Second International Reference Preparation. Each sample was diluted in assay medium containing 78% α -MEM, 20% heat inactivated fetal 5 bovine serum, 1% β -mercaptoethanol and 1% penicillin/streptomycin/fungizone. The assay is routine and familiar to one of skill in the art.

The conditioned medium of COS1 cells transfected with pcDNA/EPO-EPO contained *in vitro* bioactivity of 45-72 U/ml, 10 and the medium from COS1 cells transfected with pcDNA-EPO contained 5 U/ml. Conditioned media from cells transfected with pcDNA and untransfected cells showed no EPO activity.

The specific activity (U/ μ g) of EPO dimer and monomer was calculated by dividing the *in vitro* bioassay value 15 (U/ml) by the concentration of protein as determined by ELISA (μ g/ml). As shown in Table 1 the specific activity of the EPO^{wt}-L-EPO^{wt} dimer was 1007 U/ml compared to EPO monomer with a specific activity of 350 U/ml. Thus, dimeric proteins comprising wildtype EPO are secreted from 20 COS1 cells at enhanced rates and have increased biological and specific activity compared to monomeric wildtype EPO, in excess of twice the amount that would be predicted for a fusion protein composed of two units.

-62-

TABLE 1 BIOLOGICAL ACTIVITY AND PROTEIN CONCENTRATION IN
TRANSFECTED COS1 CELL MEDIUM

	Construct	Protein secreted		Specific Activity
		Bioassay U/ml	ELISA μg/ml	
5	Epo ^{wt}	6.3	0.018	350
	Epo ^{wt} /Epo ^{wt}	151	0.150	1007
10	Epo ^{R103A} /Epo ^{wt}	135	0.281	480
	Epo ^{wt} /Epo ^{R103A}	123	0.238	516
	Epo ^{R103A} /Epo ^{R103A}	ND	ND	---

ND = nondetectable

EXAMPLE 5

15 IN VIVO ACTIVITY OF EPO-EPO DIMERS

Conditioned medium from COS1 cells transfected with pcDNA/EPO-EPO was used to inject mice (B6C3F1 strain, female, 18 g, Jackson Labs). The haematocrits of these mice were measured prior to administering EPO-EPO (Pre-treatment values). Mice were injected subcutaneously (EPO-EPO 300 IU per kg) on day 1, day 3, and day 5 and post-treatment haematocrits determined 7 days later in day 8 of the experimental treatment regimen. Mouse #1 showed an increase haematocrit of 4.5% and mouse #2 an increase of 25 1.5%.

In another more extensive series of experiments, mice received a single injection on day 1 of the treatment regimen of conditioned media from COS1 cells transfected

-63-

with either pcDNA/EPO-EPO (n=4 mice) or pcDNA/EPO (n=4 mice). As a control, another group of mice (n=4 mice) received a single dose of conditioned media from COS1 cells. Post-treatment hematocrits were determined 7 days 5 later or on day 8 of the treatment regimen and compared to pre-treatment (day 0) values.

As shown in Figures 17A, 17B, and 17C a substantial increase in hematocrits, compared to pre-treatment values, was observed only in mice injected with conditioned media 10 containing the EPO-EPO dimer. No increase in hematocrit was observed in mice treated with EPO monomer or with control culture media. These *in vivo* data suggest that the EPO-EPO dimer has a prolonged plasma half-life.

EXAMPLE 6

15 OLIGONUCLEOTIDE-DIRECTED MUTAGENESIS OF FUSION PROTEINS

Mutations in nucleic acid constructs encoding the fusion proteins of the invention, for example EPO, can be prepared using oligonucleotide-directed mutagenesis according to the Altered Sites™ *In Vitro* Mutagenesis System 20 kit (Promega Corporation of Madison, WI). The Altered Sites™ System is based on experimental protocols routine to one of ordinary skill in the art of molecular biology. The kit consists of a unique mutagenesis vector and a simple, straightforward procedure for selection of oligonucleotide- 25 directed mutants. The system is based on the use of a second mutagenic oligonucleotide to confer antibiotic resistance to the mutant DNA strand. The system employs a

-64-

phagemid vector, pSELECT-1, which contains two genes for antibiotic resistance. One of these genes, for tetracycline resistance, is always functional. The other, for ampicillin resistance, is inactivated. An 5 oligonucleotide is provided which restores ampicillin resistance to the mutant strand during the mutagenesis reaction. This oligonucleotide is annealed to the single-stranded DNA (ssDNA) template at the same time as the mutagenic oligonucleotide and subsequent synthesis and 10 ligation of the mutant strand links the two. The DNA is transformed into a repair minus strain *E. coli*, or other suitable host, and the cells are grown in the presence of ampicillin, yielding large numbers of colonies. A second round of transformation in JM109, or a similar host, 15 ensures proper segregation of mutant and wild type plasmids and results in a high proportion of mutants.

The pSELECT-1 plasmid is a phagemid, defined as a chimeric plasmid containing the origin of a single-stranded DNA bacteriophage. This phagemid produces ssDNA upon 20 infection of the host cells with the helper phage R408 or M13KO7. The vector contains a multiple cloning site flanked by the SP6 and T7 RNA polymerase promoters and is inserted into the lacZ α -peptide. Cloning of a DNA insert into the multiple cloning site results in inactivation of 25 the α -peptide. When plated on indicator plates, colonies containing recombinant plasmids are white in a background of blue colonies. The SP6 and T7 promoters may be used to generate high specific activity RNA probes from either

-65-

strand of the insert DNA. These sites also serve as convenient priming sites for sequencing of the insert. The pSELECT-1 vector carries gene sequences for both ampicillin and tetracycline resistance. However, the plasmid is
5 ampicillin sensitive because a frameshift is introduced into this resistance gene by removing the Pst I site. Therefore, propagation of the plasmid and recombinants is performed under tetracycline selection.

The pSELECT-Control vector provides a convenient
10 white/blue positive control for mutagenesis reactions. This vector is derived from the pSELECT-1 vector by removing the Pst I site within the polylinker. The resultant frameshift in the lac α -peptide inactivated β -galactosidase and leads to a white colony phenotype on
15 indicator plates. A lacZ repair oligonucleotide (supplied with the system) may be used to introduce a four base insertion which corrects the defect in the lacZ gene and restores colony color to blue. The fraction of blue colonies obtained is an indication of the mutagenesis
20 efficiency. When the lacZ repair oligonucleotide is used in combination with the ampicillin repair oligonucleotide to correct this defect, 80-90% of the ampicillin resistant colonies are blue. When the lacZ repair oligonucleotide is used alone, a mutagenesis efficiency of only 2-5% is seen.

25 The mutagenic oligonucleotide must be complementary to the single-stranded target DNA. The ssDNA produced by the pSELECT-1 phagemid is complementary to the lacZ coding strand.

-66-

The stability of the complex between the oligonucleotide and the template is determined by the base composition of the oligonucleotide and the conditions under which it is annealed. In general, a 17-20 base 5 oligonucleotide with the mismatch located in the center is sufficient for single base mutations. This provides 8-10 perfectly matched nucleotides on either side of the mismatch. For mutations involving two or more mismatches, oligonucleotides of 25 bases or longer are needed to allow 10 for 12-15 perfectly matched nucleotides on either side of the mismatch.

Routinely, oligonucleotides are annealed by heating to 70°C for 5 minutes followed by slow cooling to room temperature.

15 DNA to be mutated is cloned into the pSELECT-1 vector using the multiple cloning sites. The vector DNA is then transformed into competent cells of JM109, or a similar host, and recombinant colonies are selected by plating on LB plates containing 15 μ g/ml tetracycline, 0.5mM IPTG, and 20 40 μ g/ml X-Gal. After incubation for 24 hours at 37°C, colonies containing recombinant plasmids appear white in a background of blue colonies.

To produce single-stranded template for the mutagenesis reaction, individual colonies containing 25 pSELECT-Control or recombinant pSELECT-1 phagemids are grown and the cultures are infected with helper phage as described below. The single-stranded DNA produced is complementary to the lacZ coding strand and complementary

-67-

to the strand of the multiple cloning site. Two helper phages R408 and M13KO7 are used to provide the greatest latitude in optimizing ssDNA yields.

EXAMPLE 7

5 CONSTRUCTION AND EXPRESSION OF EPO-EPO MUTANT DIMERS

In order to determine whether one or both EPO domains of the EPO-EPO fusion protein are biologically active, mutant EPO-EPO dimers were constructed. A single point mutation (R103A) wherein the arginine at position 103 is 10 replaced with an alanine residue in human recombinant monomeric EPO results in complete inactivation of the protein (Grodberg et al., *Eur. J. Biochem* 218:597-601 (1993); and Matthews et al., *Proc. Natl. Acad. Sci. USA* 93:9471-9476 (1996)). Therefore, the effect of the R103A 15 mutation, in one or both of the monomeric subunits of the EPO-EPO dimer, on the biological activity of the EPO-EPO dimer was determined. Point mutations, including the R103A mutation, can be made using site-directed mutagenesis techniques as described above.

20 An EPO mutation ($\text{EPO}^{\text{R103A}}$) was created in the EPO nucleic acid construct encoding the N-terminal, or C-terminal, or both N-terminal and C-terminal domains of the dimer. EPO mutant dimers ($\text{EPO}^{\text{R103A}}\text{-EPO}^{\text{wt}}$; $\text{EPO}^{\text{wt}}\text{-EPO}^{\text{R103A}}$; $\text{EPO}^{\text{R103A}}\text{-EPO}^{\text{R103A}}$) were generated using PCR and ligation 25 reaction conditions essentially as described in Example 1. Likewise methods to transfect COS1 cells with mutant dimers and techniques to prepare conditioned media for evaluation

-68-

of biological activity were also as described above for EPO^{wt}-EPO^{wt} dimers.

EXAMPLE 8

BIOLOGICAL ACTIVITY OF EPO-EPO MUTANT DIMERS

5 As discussed above, mutation of the arginine at position 103 to an alanine residue in monomeric EPO leads to a complete loss of biological activity. Thus, it was expected that a R103A mutation in one domain of an EPO-EPO dimer (EPO^{R103A}-EPO^{wt} or EPO^{wt}-EPO^{R103A}) would result in a 10 fusion protein which retained approximately half the biological activity of the EPO^{wt}-EPO^{wt} dimer. It was further expected that mutation of both domains (Epo^{R103A}/Epo^{R103A}) would result in complete inactivation of the fusion protein.

15 As shown in Table 1 (See Example 4) the EPO^{R103A}-EPO^{wt} and EPO^{wt}-EPO^{R103A} mutants were secreted from COS1 cells at concentrations surprisingly greater than the nonmutant EPO^{wt}-EPO^{wt} dimer. Mutation of a single domain of the EPO dimer resulted in an unexpectedly high *in vitro* biological 20 activity (135 U/ml for EPO^{R103A}-EPO^{wt} and 123 U/ml for EPO^{wt}-EPO^{R103A}) as determined using the Krystal bioassay. These values were only slightly lower than nonmutant EPO^{wt}-EPO^{wt} (151 U/ml) and significantly above monomeric EPO (6.3 U/ml). Thus, inactivation of one EPO molecule in a fusion 25 protein dimer does not, as would be expected, reduce the biological activity to a level observed with one protein molecule of EPO. Retention of enhanced biological activity

-69-

by the EPO^{R103A}-EPO^{wt} and EPO^{wt}-EPO^{R103A} mutant dimers could suggest that each of the two domains in EPO^{wt}/EPO^{wt} is capable of activating the EPO receptor on target cells such as spleen cells used in the bioassay.

5 Interestingly, the specific activities of EPO^{R103A}-EPO^{wt} and EPO^{wt}-EPO^{R103A} mutants were 480 U/µg and 516 U/µg, respectively, essentially one-half that of the non-mutant EPO^{wt}-EPO^{wt} dimer, indicating that the two EPO domains in the EPO^{wt}-EPO^{wt} dimer are equally active.

10 Northern blot analysis revealed that mRNA encoding the double EPO^{R103A}/EPO^{R103A} mutant was expressed. However, no biological activity or secreted fusion protein was detected in conditioned medium from COS1 cells transfected with EPO^{R103A}/EPO^{R103A} constructs.

15 EXAMPLE 9

EVALUATION OF BIOLOGICAL ACTIVITY OF RECOMBINANT
POLYPEPTIDE VARIANT PROTEINS

The biological activity of the recombinant polypeptide variants containing mutations in the 5' untranslated 20 region, or 3' untranslated region or both is determined using *in vitro* and *in vivo* assays.

The recombinant polypeptide variant proteins are preferably purified substantially prior to use, particularly where the protein could be employed as an *in* 25 *vivo* therapeutic, although the degree of purity is not necessarily critical where the molecule is to be used *in vitro*. In one embodiment, the recombinant polypeptides can

-70-

be isolated to about 50% purity (by weight), more preferably to about 80% by weight or about 95% by weight. It is most preferred to utilize a protein which is essentially pure (e.g., about 99% by weight or to 5 homogeneity) for *in vitro* and *in vivo* assays as well as *in vivo* therapeutics.

For example, recombinant EPO variant proteins, which can be prepared according to site-directed mutagenesis methods discussed in Examples 6 and 10, can be screened for 10 *in vitro* and *in vivo* activity prior to use in therapeutic settings. The *in vitro* assay measures the effect of EPO variant proteins on erythropoiesis in intact mouse spleen cells assay according to the procedure of Krystal, G., *Exp. Hematol.*, 11:649-660 (1983). To screen the various 15 recombinant EPO variant proteins for activity, for example, *in vitro* or *in vivo*, the proteins (or mixtures of the EPO proteins) can be evaluated for the extent of hematopoieses, platelet production or receptor binding. Tests to determine biological activity are well-known to those of 20 skill in the art. For example, the biological activity of EPO can be measured as described in Sytkowski and Grodberg (U.S. Patent Nos. 5,614,184); Sytkowski (U.S. Patent No. 5,580,853); Sytkowski, U.S. patient application "Modified Polypeptides with Increased Biological Activity", filed 25 February 3, 1998; and Powell (U.S. Patent No. 5,688,679); the teachings of which are herein incorporated by reference in their entirety.

-71-

EXAMPLE 10

POLYPEPTIDE VARIANTS PRODUCED BY ALTERING NONCODING REGIONS OF THE GENE

Typically, variants of recombinant proteins are made by deleting, adding or substituting nucleotides within the coding of the gene. However, it is also possible to make variants of recombinant proteins by altering the noncoding regions of genes, i.e., the 5' and 3' untranslated regions (UTR). Modifications in the UTR of a gene, especially in the 5' sequence as well as in the first intron, influence the regulation of translation; and, thus, the expression of proteins (Schultz, D.E., et al., *J. Virol.* 70:1041-1049, 1996; Kozak, M., *J. Mol. Biol.* 235:95-110, 1994; Bettany, A.J., et al., *J. Biol. Chem.* 267:16531-16537, 1992; Kozak, M., *J. Biol. Chem.* 266:19867-19870, 1991).

Alterations in the non-coding sequences of a polypeptide gene can result in different mRNA secondary structure (e.g., free energy of the loops and base pairs), translation efficiency; and subsequently, the expression, secretion and biological activity of the polypeptide. Therefore, different forms of polypeptides can be manufactured as a result of modifications in regions which flank either the 5' or 3' side of the coding region of a polypeptide.

Figure 12 is a schematic representation of changes in mRNA structure and ultimately protein structure and function that can result when an alteration(s) is made in the 5' and/or 3' UTR of the recombinant polypeptide gene.

-72-

Variations in the recombinant polypeptide can be produced as, for example, different restriction enzyme generated fragments of genomic sequences and/or specific nucleotide substitutions and mutations in the 5' and/or 3' UTR of the 5 polypeptide coding sequence. Oligonucleotide-directed site-specific mutagenesis procedures as described herein can be employed to provide the recombinant polypeptide variant proteins.

Modifications in the noncoding regions of the 10 polypeptide gene can affect mRNA stability, rates of translation, expression from host cells, protein processing, export from rough endoplasmic reticulum, extent and pattern of glycosylation, secretion dynamics and rates of export from the cell. For example, varied glycosylation 15 patterns can result, which, for EPO, are of great importance for biological activity (Yamaguchi, K., et al., *J. Biol. Chem.* 266:20434-20439, 1991). The resulting proteins can represent chemically, structurally and biologically distinct forms of recombinant polypeptides.

The nucleotide sequences of polypeptide variants can be confirmed by DNA sequencing using standard experimental procedures. Distinctive versions of genomic polypeptides can be produced by mutations in the 5' and 3' UTR and can be detected by Southern blotting. Likewise, different 20 mRNAs can be identified by Northern blotting. Differences in hybridization conditions, i.e., high or low stringencies, will be an index of the diversity of the DNA and mRNA. It is possible that different genomic sequences 25

-73-

may require different promoters (e.g., mouse metallothionein or 3-phosphoglycerate), vectors (e.g., bovine papilloma virus), and/or host cells (e.g., CHO, BHK-21 or C127 cells) to adequately express the recombinant polypeptide. The technical methods which can be employed for the above mentioned experimental strategies are familiar to those of skill in the art. For example, detailed protocols can be found in Sambrook, et al., "Molecular Cloning: A Laboratory Manual," (1989) and Ausubel, et al., "Current Protocols in Molecular Biology," (1995); Powell, J.S., et al., *Proc. Natl. Acad. Sci. USA* 83:6465-6469, 1986; and Sytkowski and Grodberg, (U.S. Patent No. 5,614,184); Sytkowski (U.S. Patent No. 5,580,853); and Powell (U.S. Patent No. 5,688,679); the teachings of which are herein incorporated by reference in their entirety.

Mutations in the 5' and/or 3' UTR of the polypeptide gene can result in altered RNA structure, total free energy, stability and/or rates and efficiency of translation (Schultz, D.E., et al., *J. Virol.* 70:1041-1049, 1996; Kozak, M., *J. Mol. Biol.* 235:95-110, 1994; Bettany, A.J., et al., *J. Biol. Chem.* 267:16531-16537, 1992; Kozak, M., *J. Biol. Chem.* 266:19867-19870, 1991; Purvis, I.J., et al., *Nucleic Acids Res.* 15: 7951-62, 1987). The secondary structure of mRNAs play an important role in the initiation and efficiency of translation and, thus, in protein synthesis.

-74-

Computer modeling using the PC/Gene® RNAFOLD program (IntelliGenetics, Inc.) is used to predict differences in RNA secondary structure, specifically the total free energy, following deletion in the 5' or 3' UTR of, for example, the EPO gene (Figures 13-15). The program utilizes an algorithm which calculates the energies of the secondary structure of RNA. It automatically transcribes any DNA sequence into a single stranded RNA sequence. Since the mRNA is single stranded, it can fold back upon itself due to the complementarity of bases resulting in various "loops". Energy must be released to form a base-paired or looped structure and the stability of the resulting secondary structure is determined by the amount of energy released. Therefore, if alternative structures have a free energy of formation of -50 kcal/mol and -100 kcal/mol, the latter structure is intrinsically more likely to be formed.

For example, free energy for the secondary RNA structure for nucleotides 401-624 in the 5' UTR of the EPO gene is predicted to be -161.0 kcal/mol (SEQ ID NO: 2). A 50 nucleotide deletion spanning nucleotides 501-550 results in a total free energy of -127.2 kcal/mol (SEQ ID NO: 3), whereas a 50 nucleotide deletion at nucleotides 551-600 (SEQ ID NO: 4) results in an RNA structure with -118.9 kcal/mol of free energy indicating the importance of the size of the deletion and location in ultimately defining mRNA secondary structure. Larger deletions, in different portions of the 401-624 region of the 5' UTR, yield RNA

-75-

structures with varying predicted energy states (SEQ ID NOS: 5-7). These results are summarized in Table 2.

TABLE 2: SEQUENCE VARIATION IN 5' UTR-
EFFECT ON mRNA FREE ENERGY

Sequence	SEQ ID NO:	Nucleotide Length (bp)	Region of Deletion	Number of Nucleotide Deleted (bp)	Free Energy (kal/mol)
Native	2	224	---	---	-161.0
5'a	3	174	501-550	50	-127.2
5'b	4	174	551-600	50	-118.9
5'c	5	124	401-550	100	-94.1
5'd	6	74	401-550	150	-52.3
5'e	7	34	401-590	190	-11.3

Likewise, for example, the free energy for the RNA
15 secondary structure for nucleotides 2773-2972 in the 3' UTR
of the EPO gene is predicted to be -81.4 kcal/mol (SEQ ID
NO: 8). A 50 nucleotide deletion spanning nucleotides
2923-2972 (SEQ ID NO: 9) results in a total free energy of
-53.5 kcal/mol, whereas a 100 nucleotide deletion at
20 nucleotides 2873-2972 (SEQ ID NO: 10) results in an RNA
structure with -33.3 kcal/mol of free energy. Larger
deletions, in different portions of the 2773-2973 region of
the 3' UTR, yield RNA structures with varying predicted
energy states (SEQ ID NOS: 11 and 12). These results are
25 summarized in Table 3.

-76-

TABLE 3: SEQUENCE VARIATION IN 3' UTR-
EFFECT ON mRNA FREE ENERGY

Sequence	SEQ ID NO:	Nucleotide Length (bp)	Region of Deletion	Number of Nucleotide Deleted (bp)	Free Energy (kal/mol)
Native	8	200	---	---	-81.4
3'a	9	150	2923-2972	50	-53.5
3'b	10	100	2873-2972	100	-33.3
3'c	11	50	2823-2972	150	-12.5
3'd	12	100	2801-2900	100	-36.6

- 10 The secondary structure of mRNA affects the rates of translation of the corresponding coding regions (Kikinis, Z., et al., *Nucleic Acids Res.* 23: 4190-4195, 1995; Kozak, M., *Mamm. Genome* 7: 563-574, 1996; Bettany, A.J., et al., *J. Biol. Chem.* 267: 16531-16537, 1992; Kozak, M., *J. Mol. Biol.* 235: 95-110, 1994). Secondary structure loops in the mRNA must be unwound to facilitate ribosome attachment and proper protein assembly (Alberts, B., et al., "Molecular Biology of the Cell", 3rd ed., Garland Publishing, Inc., New York, NY, pp. 223-290, 1994).
- 15 The nascent polypeptide chains can interact with chaperon proteins, for example, BiP, in unique ways which can affect the proper folding of the polypeptide chain and influence passage of the protein through the endoplasmic
- 20

-77-

reticulum thereby altering glycosylation of the resulting protein. Recent data suggest that BiP-like proteins not only bind improperly folded proteins but also may assist in the appropriate protein folding and facilitate the membrane
5 translocation and glycosylation of secretory proteins
(Knittler, M.R., et al., *EMBO J.* 11:1573-1581, (1992);
Sanders, S.L. et al., *Cell* 69:353-365, (1992)).
Alterations in glycosylation patterns can influence the secretion and, in the case of EPO, drastically alter
10 biological activity (Yamaguchi, K., et al., *J. Biol. Chem.* 266:20434-20439, 1991).

The three dimensional structure of a polypeptide, for example EPO, is significantly influenced by the protein backbone and the oligosaccharide chains. Alterations in the
15 carbohydrate composition (e.g., the number of N- or O-linked oligosaccharide residues and/or type of sugar moieties) can lead to different biological properties of the polypeptide variant proteins and, thus, varied therapeutic effects. Therefore, a difference in the 5' or
20 3' UTR can affect mRNA secondary structure, which in turn can influence the rate of expression and post-translational modifications such as glycosylation. The proper glycosylation of a polypeptide can be of paramount importance to proper folding and secretion of the mature
25 product and, hence, its biological and pharmacological properties.

Indices of intrinsic structural variations in the recombinant polypeptide variant proteins can be manifested

-78-

in differences in the three-dimensional structure of the protein backbone and the extent and pattern of carbohydrate chains. For example, circular dichroism (CD) spectra and thermal stability for the resulting polypeptide variants
5 can be performed to determine the content of alpha helix, beta sheet, beta turn and random coil for different glycoproteins. The structure of the oligosaccharide chains can be determined, for example, using enzymatic and chemical deglycosylation, gas chromatography, methylation analyses, fast-atom-bombardment mass spectrometry as well
10 as one-and two-dimensional ¹H-NMR spectrometry. The methods to perform the above mentioned analyses are routine to one of ordinary skill in the art and are delineated in detail in several references including for example,
15 Ausubel, F.M., et al., "Current Protocols in Molecular Biology" (1995); Nimtz, M., et al. *Eur. J. Biochem.* 213: 39-56, 1993; and Nimtz, M., et al., *FEBS* 365: 203-208, 1995, the teachings of which are herein incorporated by reference in their entirety.
20 In addition, assessment of the structural differences in the recombinant polypeptide variant proteins could be evaluated using immunoprecipitation with polypeptide-specific monoclonal antibodies and heat denaturation curves. Experimental techniques to measure these
25 properties of a polypeptide, for example, EPO, are described in Sytkowski and Grodberg (U.S. Patent No. 5,614,184); Sytkowski (U.S. Patent No. 5,580,853); and

-79-

Powell (U.S. Patent No. 5,688,679); the teachings of which are herein incorporated by reference in their entirety.

EQUIVALENTS

5 While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the
10 invention as defined by the appended claims. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are intended to be
15 encompassed in the scope of the claims.

-80-

CLAIMS

What is claimed is:

- 5 1. A fusion protein with increased biological activity comprising two or more protein molecules.
2. The fusion protein of Claim 1 having an increased rate of secretion.
- 10 3. The fusion protein of Claim 1, wherein said protein molecules comprise erythropoietin.
4. An isolated nucleic acid encoding the erythropoietin fusion protein of Claim 3 comprising SEQ ID NO: 16.
- 15 5. The erythropoietin fusion protein of Claim 3 comprising the amino acid sequence, SEQ ID NO: 17.
- 20 6. The fusion protein of Claim 1 or Claim 2, wherein said protein molecules are linked by a peptide linker.
7. The fusion protein of Claim 6, wherein said peptide linker allows the protein molecules to rotate freely relative to each other.
- 25

-81-

8. The fusion protein of Claim 6 or Claim 7, wherein said peptide linker is from about 10 amino acids to about 20 amino acids in length.
- 5 9. The fusion protein of Claim 8, wherein said peptide linker is about 15 amino acids in length.
10. The fusion protein linker of Claims 6-9, wherein said amino acids are selected from the group consisting of Glycine, Serine, Asparagine, Threonine and Alanine.
11. A nucleic acid comprising a nucleotide sequence which encodes a fusion protein with increased biological activity comprising two or more protein molecules.
- 15 12. A vector comprising said nucleic acid of Claim 11.
13. A host cell transfected with the vector of Claim 12.
- 20 14. A composition comprising a fusion protein of any one of Claims 1-10 and a pharmaceutically acceptable carrier.
- 25 15. A method for producing a fusion protein comprising culturing the cell of Claim 13 in a suitable medium to produce a fusion protein.

-82-

16. A method of treating or preventing a condition or deficiency in a mammal in need of such treatment comprising administering to the mammal a therapeutically effective amount of a fusion protein
5 of anyone of Claims 1-10 or the fusion protein encoded by the nucleic acid of Claim 11.
17. A method of treating or preventing anemia in a mammal comprising administering to the mammal a therapeutically effective amount of said fusion protein of Claim 3 (or any one of Claims 4-10 as a dependent on Claim 3).
10
18. An isolated nucleic acid encoding a fusion protein comprising two or more molecules, wherein the fusion protein has altered biological activity and wherein the nucleic acid has, one or more mutations in a noncoding region of the nucleic acid.
15
- 20 19. The nucleic acid of Claim 18 wherein a mutation is in the 5' noncoding region.
20. The nucleic acid of Claim 19 wherein the nucleic acid encodes an erythropoietin fusion protein and comprises a nucleic acid selected from the group consisting of SEQ ID NO: 3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO: 6 and SEQ ID NO: 7.
25

-83-

21. A method of treating or preventing a condition or deficiency in a mammal in need of such treatment comprising administering to the mammal a therapeutically effective amount of a fusion protein
5 encoded by the nucleic acid of any one of Claims 18-21.
22. A composition comprising a fusion protein encoded by the nucleic acid of Claims 19-20 and a pharmaceutically acceptable carrier.
10
23. A method of treating or preventing anemia in a mammal comprising administering to the mammal a therapeutically effective amount of a fusion protein
15 encoded by a nucleic acid of Claim 20.
24. The nucleic acid of Claim 18 wherein a mutation is in the 3' noncoding region.
20
25. The nucleic acid of Claim 24 wherein the nucleic acid encodes an EPO fusion protein and comprises a nucleic acid selected from the group consisting of SEQ ID NO:
9; SEQ ID NO: 10; SEQ ID NO: 11; and SEQ ID NO: 12.
26. A method of treating or preventing a condition or deficiency in a mammal in need of such treatment comprising administering to the mammal a
25

-84-

therapeutically effective amount of a fusion protein encoded by the nucleic acid of Claim 24 and Claim 25.

27. A composition comprising a fusion protein of Claim 24 or Claim 25 and a pharmaceutically acceptable carrier.
5
28. A method of treating or preventing anemia in a mammal comprising administering to the mammal a therapeutically effective amount of a fusion protein
10 encoded by a nucleic acid of Claim 25.
29. The nucleic acid of Claim 18 wherein a mutation is in both the 5' and 3' noncoding regions.
15
30. The nucleic acid of Claim 29 wherein the nucleic acid encodes an EPO fusion protein and comprises a nucleic acid selected from the group consisting of SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; and
20 SEQ ID NO: 12.
31. A method of treating or preventing a condition or deficiency in a mammal in need of such treatment comprising administering to the mammal a therapeutically effective amount of a fusion protein
25 encoded by the nucleic acid of Claim 29.

-85-

32. A composition comprising a fusion protein of Claim 29 and a pharmaceutically acceptable carrier.
33. A method of treating or preventing anemia in a mammal comprising administering to the mammal a therapeutically effective amount of a fusion protein encoded by a nucleic acid of Claim 30.
5
34. A fusion protein with increased biological activity comprising two or more protein molecules wherein at least one protein molecule has one or more mutations.
10
35. The fusion protein of Claim 34 wherein said protein molecules comprise erythropoietin.
36. The erythropoietin fusion protein of Claim 35 wherein at least one of the erythropoietin molecules has a mutation wherein the arginine residue at position 103 is replaced with alanine.
37. A nucleic acid encoding a fusion protein of Claim 34.
38. A nucleic acid encoding a fusion protein of Claim 36.
39. A method of treating or preventing anemia in a mammal comprising administering to the mammal a therapeutically effective amount of the erythropoietin fusion protein of Claim 36.

-86-

40. A composition comprising a fusion protein of Claim 36 and a pharmaceutically acceptable carrier.
41. The fusion protein of any one of Claims 1-10 or the fusion encoded by the nucleic acid of any one of Claims 11, 18-20, 24-25 and 29-30 for use in therapy or prophylaxis, for example in treating or preventing a condition or deficiency in a mammal in need of such treatment.
42. Use of the fusion protein of any one of Claims 1-10 or the fusion protein encoded by the nucleic acid of any one of Claims 11, 18-20, 24-25 and 29-30 for the manufacture of a medicament for use in therapy or prophylaxis, for example in treating or preventing a condition or deficiency in a mammal in need of such treatment.
43. A process for the production of a therapeutic or prophylactic composition (for example, for treating or preventing a condition or deficiency in a mammal in need of such treatment) characterized in the use, as an essential constituent of said composition, of the fusion protein or any one of Claims 1-10 or the fusion protein encoded by the nucleic acid of any one of Claims 11, 18-20, 24-25 and 29-30.

-87-

44. The fusion protein of Claim 41, use of Claim 42 or process of Claim 43 wherein the fusion protein comprises erythropoietin and the therapy or prophylaxis is the treatment or prevention of anaemia.





FIG. 1



SUBSTITUTE SHEET (RULE 26)

FIG. 2

3/25




FIG. 3




FIG. 4




FIG. 5




FIG. 6 BglII restriction digests: ① **EpoA^{IV}** Forward Direction \oplus
2396bp, 1461bp, 305bp
② **EpoA^{IV}** Reverse Direction \ominus
2051bp, 1806bp, 305bp




FIG. 7 BglII restriction digests: ① **EpoB^I** Forward Direction \oplus
2356bp, 1381bp, 305bp
② **EpoB^I** Reverse Direction \ominus
1971bp, 1766bp, 305bp




FIG. 8 ScaI and XhoI restriction digests: 3485bp, 6776bp




FIG. 9 BamHI and ScaI restriction digests: 3485bp, 5576bp





FIG. 10 XhoI and BamHI restriction digest: 5376bp, 56bp

SUBSTITUTE SHEET (RULE 26)



NgoMI restriction digest of pcDNA3-1-Epo-Epo: 393 bp, 1342 bp, 1054 bp, 2836 bp

FIG. 11




FIG. 12

9/25

aagcttctgg	gcttccagac	ccagctactt	tgcggaaactc	agcaacccag	gcatctctga	60
gtctccgccc	aagaccggga	tgcggggccag	gggaggtgtc	cgggagccca	gcctttcccc	120
gatagcacgc	tccgcccagt	ccaagggtgc	gcaaccggct	gcactccct	cccgcgaccc	180
aggggcccccggg	agcagcccc	atgaccaca	cgcacgtctg	cagcagcccc	gctcacgccc	240
cgggcgagccct	caacccaggc	gtccctgcccc	tgctctgacc	ccgggtggcc	cctacccctg	300
gcgacccctc	acgcacacag	cctctccccc	accccccaccc	gegcacgac	acatgcagat	360
aacagccccg	accccccggcc	agagccgcag	agtccctggg	ccacccggc	cgtcgctgc	420
gctgcgcggc	accgcgcgt	cctcccgag	ccggaccggg	gccaccgc	ccgcctctgct	480
ccgacacccgc	gccccctgga	cagcgcct	ctccctctagg	cccggtgggc	tggccctgca	540
ccgcccggatc	tcccgggatg	aggggccccc	gtgtggtcac	ccggcgcgc	ccaggtcgt	600
gagggacccc	ggccaggcgc	ggagatgggg	gtgcacggg	agtactcg	ggctggggcgc	660
tcccgccggcc	cgggtccctg	tttgagcggg	gatttagcgc	cccggtatt	ggccaggagg	720
tggctgggtt	caaggacccg	cgacttgtca	aggacccccc	aagggggagg	gggggtggggc	780
agcctccacg	tgccagcggg	gacttggggg	agtccctggg	gatggaaaa	acctgacactg	840
tgaaggggac	acagttttgg	ggttgagggg	aagaaggttt	gggggttctg	ctgtgcgcagt	900
ggagagggaa	ctgataagct	gataacctgg	gcgcgtggagc	caccacttat	ctgcccagagg	960
ggaagccctt	gtcacaccag	gattgaagtt	tggccggaga	agtggatgt	ggtagctggg	1020
ggtgggggtgt	gcacacggca	gcaggattga	atgaaggcca	gggaggcagc	acctgagtgc	1080
ttgcatgggtt	ggggacagga	aggacgagct	ggggcagaga	cgtggggatg	aaggaagctg	1140
tccttccaca	gccacccttc	tccctcccc	cctgactctc	agcctggcta	tctgttctag	1200
aatgtctgc	ctggctgtgg	tttctctgt	ccctgctgtc	gctccctctg	ggcctcccag	1260
tcctggggcgc	cccaccacgc	ctcatctgt	acagccgagt	cctggagagg	taccttttgg	1320

Figure 13A.

10/25

aggccaagga ggccgagaat atcacggta gacccttcc ccagcacatt ccacagaact	1380
cacgcgtcagg gcttcaggg aactctccc gatccaggaa cctggactt ggtttggggt	1440
ggagttggga agcttagacac tgcccccta cataagaata agtctggtg ccccaaacca	1500
tacctggaaa ctaggcaagg agcaaagcca gcagatccta cggcctgtgg gccagggcca	1560
gagccttcag ggacccttga ctccccggc ttgtgcatt tcagacggc ttgtctgaac	1620
actgcagctt gaatgagaat atcaactgtcc cagacaccaa agttaatttc tatgccttgg	1680
agaggatgga ggtgagtttcc ttttttttt tttttctttt cttttggaga attcatttg	1740
cgagcctgtat ttggatgaa aggagaatg atcgggggaa agtaaaatg gaggcagcaga	1800
gatgaggctg cctgggcgcg gaggtcacg tctataatcc caggctgaga tggccgagat	1860
gggagaattt cttgagccct ggaggttcag accaacctag gcagcatagt gagatcccc	1920
atctctacaa acatttaaa aaattagtca ggtgaagtgg tgcattgtgg tagtcccaga	1980
tatitggaaag gctgaggcgg gaggatcgct tgagcccagg aatttgaggc tgcagtgagc	2040
tgtgatcaca ccactgcaact ccagcctcag tgacagagtg aggcctgtc tcaaaaaaga	2100
aaagaaaaaa gaaaaataat gaggctgta tggaaatacat tcattattca ttcaactca	2160
cactcactca ttcattcatt cattcattca acaagtctta ttgcataacct tctgtttgt	2220
cagcttggtg ctggggctg ctgaggggca ggagggagag ggtgacatgg gtcagctgac	2280
tcccagagtc cactccctgt aggtcgggca gcaggccgt aaggtctggc agggcctggc	2340
cctgctgtcg gaagctgtcc tgcggggcca ggcectgtt gtcaactt cccagccgtg	2400
ggagccccctg cagctgcatt tggataaaagc cgtcagtggc cttegcagcc tcaccactt	2460
gcttcgggct ctgggagggc aggtgagtag gagcggcacac ttctgttgc ctttctgt	2520
agaaggggag aagggtctt ctaaggagta caggaactgt ccttatttctt tccctttctg	2580
tggcactgca ggcacccctt gtttcttctt tggcagaagg aagccatctc ccctccagat	2640
gcggccctcag ctgctccact ccgaacaatc actgctgaca ctttccgcaa actttccga	2700
gtctactcca atttcctccg gggaaagctg aagctgtaca caggggaggc ctgcaggaca	2760
ggggacagat gaccaggtgt gtccacctgg gcatatccac cacctccctc accaacattt	2820
cttgcgccac accctccccc gccactcctg aacccctcg agggctctc agtcagcgc	2880
cagcctgtcc catggacact ccagtgccag caatgacatc tcagggccca gaggaactgt	2940

Figure 13B

11/25

ccagagagca actctgagat ctaaggatgt cacagggcca acttgagggc ccagagcagg	3000
aagcattcag agagcagctt taaaactcagg gacagagcca tgctggaaag acgcctgagc	3060
tcactcgcca ccctgcaaaa ttgtatgcc a gacacgctt tggaggcgat ttacctgttt	3120
tcgcaccc tac catcaggac aggtgaccc ggagaactt ggtggcaagc tgtgacttct	3180
ccaggtctca cgggcatggg cactccctt g tggcaagag cccccttgac accgggggtgg	3240
tgggaaccat gaagacagga tgggggctgg cctctggctc tcatggggtc caagttttgt	3300
gtatttctca acctcattga caagaactga aaccaccaat atgactctt gctttctgt	3360
tttctggaa cctccaaatc ccctggctc gtcccactcc tggcagcagt gcagcaggc	3420
caggtccggg aaatgaggggg tggagggggc tggccctac gtgctgtc acacagcctg	3480
tctgacctct cgacctaccc gcctaggcca caagctctgc ctacgctggt caataagggtg	3540
tctccattca aggccctcacc gcagtaaggc agctgccaac cctgcccagg gcaaggctgc	3600
ag	3602

Figure 13C

12/25

ccacccccggc cgctcgctgc gctgcgccgc accgcgtgt cctccggag ccggaccggg	60
gccacccggc cccgtctgtct ccgacaccgc gcccccttggaa cagccgcct ctccctctagg	120
cccggtggggc tggcccttca ccgcgcgatct tcccgggatg agggcccccg gtgtggtcac	180
ccggcgccgc ccaggtcgct gagggacccc ggccaggcgc ggag	224

Figure 14A

13/25

ccacccccggc cgctcgctgc gctgcccgc accgcgtgt cctccggag ccggaccggg	60
gccacccgcgc ccgctctgct cccgacaccgc gccccctgga tccccggatg agggcccccg	120
gtgtggtcac cccggcgcgc ccaggctcgct gagggacccc ggccaggcgc ggag	174

Figure 14B

14/25

ccacccggc cgctcgctgc gctgcgcccgc accgcgcgtgt cctccccggag ccggaccgggg	60
gccaccgcgc ccgcctctgct ccgcacacgc gccccccgttga cagccgcctt ctccctcttagg	120
cccggtggggc tggccctgca ccgcgcgatc gagggacccc ggccaggcgc ggag	174

Figure 14C

15/25

cagccgcctt	ctcctctagg	cccggtgggc	tggccctgca	ccgcccagct	tccccggatg	60
aggcccccg	gtgtggtcac	ccggcgcc	ccaggtcgct	gagggacccc	ggccaggcgc	120
ggag						124

Figure 14D

16/25

tccccgggatg agggcccccgt gtgtggtcac ccggcgcgcc ccaggtcgct gagggacccc 60
ggccaggcgc ggag 74

Figure 14E

17/25

ccaggtcgct gagggacccc ggccaggcgc ggag

34

Figure 14F

18/25

ccaggtgtgt ccacctgggc atatccacca cctccctcac caacattgct tggccacac	60
cctccccgc cactcctgaa ccccgtag gggcttcag ctcagcgcca gcctgtccc	120
tggacactcc agtgccagca atgacatctc aggggccaga ggaactgtcc agagagcaac	180
tctgagatct aaggatgtca	200

Figure 15A

19/25

ccaggtgtgt ccacctgggc atatccacca cctccctcac caacattgct tgtgccacac 60
cctccccccgc cactcctgaa ccccgtagag gggctctcag ctcagcgcca gcctgtcccc 120
tggacaactcc agtgccagca atgacatctc 150

Figure 15B

20/25

ccaggtgtt ccacctggc atatccacca cttccctcac caacattgct tgtgccacac 60
ctccccccgc cactcctgaa ccccgtcgag gggctctcag 100

Figure 15C

21/25

ccaggtgtgt ccacctgggc atatccacca cctccctcac caacattgct

50

Figure 15D

ccaggtgtgt ccacctgggc atatccaccc agtgcagca atgacatctc aggggccaga

60

ggaactgtcc agagagcaac tctgagatct aaggatgtca

100

Figure 15E

22/25

aggcgccggag atg ggg gtg cac gaa tgt cct gcc tgg ctg tgg ctt ctc	49
Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu	
1 5 10	
ctg tcc ctg ctg tcg ctc cct ctg ggc ctc cca gtc ctg ggc gcc cca	97
Leu Ser Leu Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro	
15 20 25	
cca cgc ctc atc tgt gac agc cga gtc ctg gag agg tac ctc ttg gag	145
Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu	
30 35 40 45	
gcc aag gag gcc gag aat atc acg acg ggc tgt gct gaa cac tgc agc	193
Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser	
50 55 60	
ttg aat gag aat atc act gtc cca gac acc aaa gtt aat ttc tat gcc	241
Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala	
65 70 75	
tgg aag agg atg gag gtc ggg cag cag gcc gta gaa gtc tgg cag ggc	289
Trp Lys Arg Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly	
80 85 90	
ctg gcc ctg ctg tcg gaa gct gtc ctg cgg ggc cag gcc ctg ttg gtc	337
Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val	
95 100 105	

Figure 16A

23/25

aac tct tcc cag ccg tgg gag ccc ctg cag ctg cat gtg gat aaa gcc Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala 110 115 120 125	385
gtc agt ggc ctt cgc agc ctc acc act ctg ctt cgg gct ctg gga gcc Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala 130 135 140	433
cag aag gaa gcc atc tcc cct cca gat gcg gcc tca gct gct cca ctc Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu 145 150 155	481
cga aca atc act gct gac act ttc cgc aaa ctc ttc cga gtc tac tcc Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser 160 165 170	529
aat ttc ctc cgg gga aag ctg aag ctg tac aca ggg gag gcc tgc agg Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg 175 180 185	577
aca ggg gac aga gcc ggc ggt ggt gga tct ggt ggc ggt gga tcc ggt Thr Gly Asp Arg Ala Gly Gly Ser Gly Gly Gly Ser Gly 190 195 200 205	625
ggc ggc ggc agt act gcc cca cca cgc ctc atc tgt gac agc cga gtc Gly Gly Ser Thr Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val 210 215 220	673
ctg gag agg tac ctc ttg gag gcc aag gag gcc gag aat atc acg acg Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr 225 230 235	721

Figure 16B

24/25

ggc tgt gct gaa cac tgc agc ttg aat gag aat atc act gtc cca gac Gly Cys Ala Glu His Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp	769
240 245 250	
acc aaa gtt aat ttc tat gcc tgg aag agg atg gag gtc ggg cag cag Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg Met Glu Val Gly Gln Gln	817
255 260 265	
gcc gta gaa gtc tgg cag ggc ctg gcc ctg tcg gaa gct gtc ctg Ala Val Glu Val Trp Gln Gly Leu Ala Leu Leu Ser Glu Ala Val Leu	865
270 275 280 285	
cgg ggc cag gcc ctg ttg gtc aac tct tcc cag ccg tgg gag ccc ctg Arg Gly Gln Ala Leu Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu	913
290 295 300	
cag ctg cat gtg gat aaa gcc gtc agt ggc ctt cgc agc ctc acc act Gln Leu His Val Asp Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr	961
305 310 315	
ctg ctt cgg gct ctg gga gcc cag aag gaa gcc atc tcc cct cca gat Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp	1009
320 325 330	
gcg gcc tca gct gct cca ctc cga aca atc act gct gac act ttc cgc Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg	1057
335 340 345	
aaa ctc ttc cga gtc tac tcc aat ttc ctc cgg gga aag ctg aag ctg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu	1105
350 355 360 365	
tac aca ggg gag gcc tgc agg aca ggg gac aga tgaccaggtg tgtccacctg Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp Arg	1158
370 375	

Figure 16C




FIG. 17A

FIG. 17B

FIG. 17C

INTERNATIONAL SEARCH REPORT

National Application No
PCT/US 98/13944

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/62 C07K19/00 C07K14/505 C12N15/85 C12N5/10
A61K38/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 25746 A (NEW ENGLAND DEACONESS HOSPITAL) 28 September 1995 see page 3, line 2 - page 5, line 29 see page 13, line 27 - page 19, line 10; examples 2,3 ----- WO 95 33057 A (MENARINI RICERCHE SUD S.P.A.) 7 December 1995	1,3,14, 16,17, 41-44
X	----- Y	1,3,6, 8-17, 41-44 6-10,18, 21-24, 26-28, 34-40
	see page 1, line 4 - line 10 see page 4, line 8 - line 21 see page 6, line 6 - page 13, line 8 ----- -----	-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

17 November 1998

Date of mailing of the international search report

04/12/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patenttaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax (+31-70) 340-3016

Authorized officer

Montero Lopez, B

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/13944

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 622 459 A (SANWA KAGAKU KENKYUSHO CO., LTD.) 2 November 1994 see page 4, line 38 – page 5, line 35 —	1,2,6,8, 11-17, 34,37, 41-43
X	LUNN E D ET AL: "Erythropoietin dimers with enhanced in vivo activity in mice." THIRTY-EIGHTH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, ORLANDO, FLORIDA, USA, DECEMBER 6-10, 1996. BLOOD 88 (10 SUPPL. 1 PART 1-2). 1996. 543A. ISSN: 0006-4971, XP002084634 see abstract 2161 —	1,3,14, 16,17, 41-44
Y	WO 92 06116 A (ORTHO PHARMACEUTICAL CORPORATION) 16 April 1992 see page 3, line 3 – line 16 see page 7, line 10 – line 17 see page 8, line 8 – line 24 see page 8, line 34 – page 9, line 35; examples 1,3 —	6-10
Y	MCGARY E C ET AL: "Post-transcriptional regulation of erythropoietin mRNA stability by erythropoietin mRNA-binding protein." JOURNAL OF BIOLOGICAL CHEMISTRY, (1997 MAR 28) 272 (13) 8628-34. JOURNAL CODE: HIV. ISSN: 0021-9258., XP002084635 United States see abstract see page 8630, left-hand column, paragraph 3 see page 8632, right-hand column, paragraph 3 – page 8634, right-hand column, paragraph 2 —	18, 21-24, 26-28
Y	WO 94 02611 A (NEW ENGLAND DEACONESS HOSPITAL) 3 February 1994 see page 3, line 13 – line 29 see page 6, line 3 – line 10 & US 5 614 184 A cited in the application —	34-40
A	WO 96 19573 A (CANGENE CORPORATION) 27 June 1996 see example 2 —	4,5,20, 25,30
		-/-

INTERNATIONAL SEARCH REPORT

national Application No PCT/US 98/13944
--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>EP 0 816 510 A (TORAY INDUSTRIES, INC.) 7 January 1998</p> <p>see page 4, line 35 – page 5, line 25 see page 6, line 24 – line 42 see page 7, line 31 – line 45 & WO 97 23639 A (TORAY INDUSTRIES, INC.) 3 July 1997</p> <p>—</p>	1,3,6,8, 11-17, 42-44
P,X	<p>SYTKOWSKI A J ET AL: "Human erythropoietin dimers with markedly enhanced in vivo activity."</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1998 FEB 3) 95 (3) 1184-8. JOURNAL CODE: PV3. ISSN: 0027-8424., XP002084636</p> <p>United States</p> <p>see abstract</p> <p>see page 1185, left-hand column, paragraph 4 – page 1188, left-hand column, paragraph 1</p> <p>—</p>	1,3,14, 16,17, 41-44
P,X	<p>SYTKOWSKI A J ET AL: "An Epo – Epo fusion protein with enhanced potency and efficacy in vivo."</p> <p>39TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, SAN DIEGO, CALIFORNIA, USA, DECEMBER 5-9, 1997. BLOOD 90 (10 SUPPL. 1 PART 1). 1997. 57A. ISSN: 0006-4971, XP002084637</p> <p>see abstract 244</p> <p>—</p>	1,3-6,8, 9,11-17, 34-44

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/13944

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:

because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 16, 17, 21, 23, 28, 31, 33, and 39
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.

2. Claims Nos.:

because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

I. National Application No

PCT/US 98/13944

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9525746	A	28-09-1995		US 5580853 A EP 0751959 A US 5747446 A	03-12-1996 08-01-1997 05-05-1998
WO 9533057	A	07-12-1995		IT FI940106 A AU 2616895 A CA 2191306 A CN 1150458 A EP 0760858 A JP 10500579 T	27-11-1995 21-12-1995 07-12-1995 21-05-1997 12-03-1997 20-01-1998
EP 622459	A	02-11-1994		JP 6306100 A	01-11-1994
WO 9206116	A	16-04-1992		AU 1157695 A AU 8735991 A CA 2069746 A EP 0503050 A JP 5502463 T PT 99107 A ZA 9107766 A	13-04-1995 28-04-1992 29-03-1992 16-09-1992 28-04-1993 31-08-1992 29-03-1993
WO 9402611	A	03-02-1994		EP 0667903 A US 5614184 A	23-08-1995 25-03-1997
WO 9619573	A	27-06-1996		AU 692968 B AU 4169296 A CA 2208013 A EP 0800577 A	18-06-1998 10-07-1996 27-06-1996 15-10-1997
EP 816510	A	07-01-1998		CA 2213512 A WO 9723639 A	03-07-1997 03-07-1997